XXXXXXXXX XXXXXXXX

2 Footnotes

INT

RO

DU

CT

ION

3

Table of Contents

Introduction General Information Scientific Program CoE Workshop Sponsors & Exhibitors

ENETS -European Neuroendocrine Tumor Society

Prof. Massimo FalconiENETS Chairman

ENETS Officec/o Charité - Universitätsmedizin BerlinCampus Virchow-KlinikumDepartment of Internal MedicineDivision of Hepatology and GastroenterologyAugustenburger Platz 113353 Berlin, Germany

Tel.: +49 (0)30 9940 4534 0Fax: +49 (0)30 9940 4534 9

E-Mail: info@enets.orgInternet: www.enets.org

Registered at:Amtsgericht Charlottenburg, Berlin, Germany, on 20 October 2004Registration Number: VR 23838 B

Responsible for content ENETS Scientific Organizing Committee Martyn Caplin GBRWouter W. de Herder NEDMassimo Falconi ITARocio Garcia-Carbonero ESPReza Kianmanesh FRADermot O’Toole IRLMarianne Pavel GERAurel Perren SUIEva Tiensuu Janson SWEBertram Wiedenmann GER

Program editorUlrike Knell

Status February 2018

Printing company Druckerei KohlMaximilianplatz 1095643 Tirschenreuth, Germany

Tel. +49 (0)9631 1281Fax. +49 (0)9631 6330

E-Mail: info@kohl-druck.deInternet: www.kohl-druck.de

Graphic design, layout and artworkLenz LeberkernGeorg-Mark-Straße 7 92703 Krummennaab, Germany

Tel.: +49 (0)170 9191 960 E-Mail: studio@lenzleberkern.com

PhotosOliver Fischer, pixabay

Imprint

ENETS Aims & Key Dates............................................................................... 5Welcome Letter from the ENETS Chairman.................................................. 7EACCME - UEMS Accreditation Statement 2018.......................................... 9

General Information........................................................................................ 10Conference Floor Plans.................................................................................. 14ENETS App...................................................................................................... 16 ENETS Scientific Organizing Committee...................................................... 18 Life Achievement Award................................................................................. 19ENETS Committees......................................................................................... 20ENETS Reviewing Committees...................................................................... 22ENETS Grant Recipients................................................................................. 23Scientific Program Overview.......................................................................... 24ENETS Supported Study................................................................................. 26 Postgraduate Course...................................................................................... 27Poster Sessions and Poster Walks................................................................ 30 Scientific Program........................................................................................... 32ENETS Supported Study................................................................................. 41Meet the Faculty............................................................................................... 42Faculty List....................................................................................................... 63 Abstract Titles.................................................................................................. 64ENETS Supported Study................................................................................. 76

CoE Workshop................................................................................................. 77

Sponsors & Exhibitors ................................................................................... 78

Legend

INT

RO

DU

CT

ION

44

INT

RO

DU

CT

ION

55

ENETS Aims & Key Dates

ENETS Aims • Improve the diagnosis and therapy of patients with neuroendocrine tumors in an international, interdisciplinary and scientific context • Coordinate research at European hospitals and health research institutes, with emphasis on basic and clinical research for the diagnosis and treatment of NETs • Further develop standards for the accreditations of ENETS Centers of Excellence (CoE) • Offer education and training for physicians and scientists at annual scientific and educational meetings • Focus on writing and updating NET guidelines for all aspects of NET care including treatment and standards of care and subsequently publicizing in medical and scientific journals • Foster the exchange of forums for young investigators • Support collaborative scientific projects of excellence • Communicate with and inform patient advocates and patient self-help groups • Cooperate with the pharmaceutical industry for the development of new diagnostic, therapeutic and information technologies • Further endorse the ENETS Registry and ENETS Centers of Excellence (CoE) throughout Europe

Current Key Dates16th Annual ENETS Conference, 6- 8 March 2019, Barcelona, Spain: • Early-Bird Registration begins 1 September 2018 • Early-Bird Registration ends 30 November 2018 • Regular Registration begins 1 December 2018 • Regular Registration ends 11 February 2019 • Late/On-Site Registration begins 12 February 2019

ENETS Abstract Submission for the 16th Annual ENETS Conference: • Submission begins 1 September 2018 • Submission ends 2 December 2018

ENETS Travel Grant Submission for the 16th Annual ENETS Conference: • Submission begins 1 September 2018 • Submission ends 2 December 2018

ENETS Grants and AwardsBecause of establishing ENETS’ new research platform – ENETS CoE Excellence Academy* – ENETS Grants and Awards Program is currently updated.

In the future ENETS’ aim will be to support outstanding eligible research projects to be realized in a tight cooperation within the ENETS Centers of Excellence.

Further outline as well as detailed participation guidelines will be published in May 2018. (www.enets.org/grants_and_awards) ENETS Travel Grants program, supporting the youngest NET researchers in participating at the Annual ENETS Conference, remains unchanged.

*1st Meeting of the ENETS CoE Excellence Academy took place on 29 November 2017 in Munich.Participients: ENETS Executive Committee, Grant recipients 2016-2017 and their lab heads/mentors/supervisors. Aim: Presentation of proposal(s) for an interdisciplinary/inter-institutional collaborative project in order to partake in cutting edge science.

INT

RO

DU

CT

ION

7

Welcome Letter

Dear Colleagues,

On behalf of the European Neuroendocrine Tumor Society (ENETS) and its Scientific Organizing Committee, it is our great pleasure to welcome you to our 15th Annual ENETS Conference in Barcelona, Spain, 7 - 9 March 2018. We have prepared an interesting and extensive program with international experts giving plenary state of the art talks ranging from newest findings in basic research in genetics and epidemiology of malign processes to current clinical research in the field of targeted therapies. The presence of the international faculty will also allow intensive discussions on current topics in workshops and informal meetings on site. All attendees are invited to have a share in our ongoing work to improve the lot of patients with neuroendocrine tumors.

ENETS is hosting the INCA / ENETS Symposium in its 2nd year and looks forward to taking the topic of unmet medical needs forward.

The three days additionally include the 8th Annual Postgraduate Course (7 March), a Nurse Session (9 March) and offer Poster Sessions including selectedPoster Walks (8 and 9 March).

The scientific program has been accredited 16 CME credits provided by UEMS - EACCME®.

Please use this 15th Annual ENETS Conference as a unique platform to learn, meet, discuss and initiate multidisciplinary and interprofessional networking.

I look forward to meeting you in the next three days. Welcome to Barcelona, welcome to ENETS!

Massimo FalconiENETS Chairman

Massimo FalconiENETS Chairman

INT

RO

DU

CT

ION

9

Accreditation Statement

EUROPEAN UNION OF MEDICAL SPECIALISTS (UEMS) EUROPEAN ACCREDITATION COUNCIL ON CME (EACCME®)

Rue de l’Industrie 24, BE- 1040 BRUSSELS T + 32 2 649 51 64 - F + 32 2 640 37 30

www.eaccme.eu - accreditation@uems.eu

Augustenburger Platz 1 13353 Berlin Germany

Brussels, 08/01/2018

Subject : EACCME® Accreditation of event reference #1034

Dear ENETS,

We are pleased to inform you that your application for EACCME® accreditation of

15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 07/03/2018-09/03/2018

has been granted 16 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).

Accreditation Statement

Accreditation by the EACCME® confers the right to place the following statement in all communication materials including the event website, the event programme and the certificate of attendance. The following statements must be used without revision:

“The 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 07/03/2018-09/03/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 16 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”

“Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”

UEMSaisbl – Union Européenne des Médecins Spécialistes IBAN BE28 0001 3283 3820 ǀ BIC (SWIFT) BPOTBEB1 ǀ VAT n° BE 0469.067.848

GE

NE

RA

L IN

FO

RM

AT

ION

10

General Information

ENETS Registration Desk – Location & TimesThe registration desk is located on the ground floor and will be open:Tuesday, 6 March 14:00 - 18:00 (Only early pre-confirmed group pick-up) Wednesday, 7 March 08:00 - 17:30Thursday, 8 March 07:00 - 18:00Friday, 9 March 08:00 - 16:00

Conference Venue AddressCentro de Convenciones Internacional de Barcelona (CCIB)GL events CCIB, SL | Willy Brandt Square 11-14 | 08019 Barcelona | Spain | www.ccib.es

ENETS Office – Location & TimesThe ENETS Office is located in Room 134 on the first floor and will be open: Wednesday, 7 March 08:00 - 17:30Thursday, 8 March 07:00 - 17:30Friday, 9 March 08:00 - 16:00

CloakroomThe cloakroom is located on the ground floor at the main entrance and has the same opening hours as the registration desk. It is also open for the Welcome Reception and the industry-sponsored symposia.

Industry ExhibitionThe exhibition hall is located on the ground floor and will be open:Thursday, 8 March 08:00 - 18:00Friday, 9 March 08:30 - 16:00

Business CenterThe ENETS business center is located in Room 118 on the first floor and has the same opening hours as the ENETS Office. Laptops and printing services, e.g. for boarding passes, are available here.

ENETS Conference App The ENETS Conference App is available in the iTunes Store and the Google Play Store. Due to policy changes by Apple you have to search for “AttendeeHub” (by CrowdCompass) in the respective stores. Once the app is downloaded to your phone, please open it and search for “ENETS” within the app. You’ll find an event called “2018 / 15th Annual ENETS Conference”, press the “Download”-Button to download the event. If you need any help installing or using the app, assistance is available at the app helpdesk at the ENETS booth. (View page 16 and 17 for instruction overview).

ENETS Booth The ENETS booth is located close to the registration desk and offers terminals for participants to view the webcasts from the Annual ENETS Conferences in 2016 and 2017 and to participate in the e-learning course NET-CME. The ENETS booth can also be used as a meeting point.

Interactive Workshops (8 March) / Nurse Workshop (8 March) These sessions have an extra fee and must be pre-registered for as attendance is limited. Registered participants must be present at the session room no later than 7:20 in the morning on 8 March 2018. No-show slots will be given to interested delegates who were assigned to a waiting list. If you signed up on the waiting list, you should be at the session room by 7:20 and must have the € 35 in cash for immediate payment.

Poster ExhibitionThe Poster Exhibition is located on the ground floor and will be open: Thursday, 8 March 08:00 - 18:00Friday, 9 March 08:30 - 16:00

GE

NE

RA

L I

NF

OR

MA

TIO

N

11

General Information

Please note that we offer Poster Walks during Poster Session A and B on 8 and 9 March 2018. Please view the schedule on page 30 and 31. The Poster Walks are offered on a first come, first serve basis and are limited to 15 participants per walk. To join the Poster Walk please sign up at the Poster Walk booth in front of the poster area in the exhibition hall.

Name Badges and Barcode-Scan for acquiring CME PointsEvery ENETS conference participant will receive a name badge with a barcode. The badge must be worn at all times in the conference venue. Every badge will be scanned BOTH before the morning and afternoon lectures at the entrance to your session. If you lose your badge, please go to the registration desk to receive a new one.

In order to receive the full amount of 16 CME credits for 7, 8 and 9 March, you must be present in the sessions and MUST make sure your badge is scanned upon entering the sessions BOTH in the morning and afternoon.

Distribution of the CME creditsWednesday, 7 March, Postgraduate Course: Morning session 3 CME credits Afternoon session 2 CME creditsThursday, 8 March: Interactive Workshop 1 CME credit Morning session 3 CME credits Afternoon session 3 CME credits Friday, 9 March: Morning session 3 CME credits Afternoon session 1 CME credit ____________________________________________ Maximum: 16 CME credits

Certificate of Attendance and AccreditationEvery conference delegate will receive a certificate of attendance and accreditation. This certificate is granted under the auspices of the UEMS accreditation authorities in Brussels. The accreditation shown on the certificate is based on your presence in the scientific sessions. In order to have all your achieved CME credits indicated on your certificate, please print your certificate on your last day before you leave the conference. Terminals to print your certificate are situated in the foyer on ground floor. You will need to scan your badge and fill out the Learner’s Feedback Evaluation Form provided to print your certificate.

ENETS Welcome ReceptionAll registered conference delegates are cordially invited to the ENETS Welcome Reception,Wednesday, 7 March 2018, 17:15 - 18:15,CCIB – Barcelona International Convention Centre, foyer on first floor.Please note that only conference delegates wearing a valid conference name badge will be granted access.

Learner’s Feedback Evaluation FormWe urge all participants to fill out a Learner’s Feedback Evaluation Form, which can be submitted at all designated terminals prior to receiving your certificate of attendance and accreditation. ENETS expresses thank you in advance for all returned evaluation forms, as your feedback is important.

Insurance & LiabilityNeither the CCIB nor ENETS will assume any responsibility whatsoever for damage or injury to persons or property during the conference.

GE

NE

RA

L IN

FO

RM

AT

ION

12

Lost & Found Lost & Found items can be brought to and retrieved at the cloakroom on the ground floor of the CCIB at the main entrance. The cloakroom has the same opening hours as the registration desk and is also open for the Welcome Reception and the industry-sponsored symposia.

Conference BagEvery participant will receive a complimentary bag at the Annual ENETS Conference 2018 which is available for pick-up at the registration desk. The following items will be included: conference program, mini program, abstract booklet, post-it notes, ballpoint pen, block of paper, microfiber cleaning cloth, cotton shopping bag with the ENETS logo and a USB flash drive containing conference program information and the ENETS Guidelines (Neuroendocrinology 2017, Vol. 105, No. 3).

Speakers Preview Room Room 119 on the first floor has been designated for conference speakers to upload and preview their presentations. Please be aware that all conference speakers must have uploaded their presentations at least one hour before expected on stage. A technician to help you will be available during the ENETS Office opening hours.

Industry – Sponsored Satellite SymposiaThe Annual ENETS Conference 2018 includes two symposia organized by the Platinum and Legacy Sponsors. Entry to these symposia is free of charge. Lunch boxes for Satellite Symposium I will be provided in room 112.

The schedule is as follows: Industry – Sponsored Satellite Symposium I: 8 March 12:45 - 14:15 Room 112 First Floor/Level P1Industry – Sponsored Satellite Symposium II: 8 March 18:50 - 20:20 Room 112 First Floor/Level P1

ExhibitionENETS will be offering conference participants a chance to gain information and learn more about NET issues from diverse and interdisciplinary areas. ENETS welcomes all participants to visit the exhibition hall on the ground floor behind the registration desk. The floor plan of the exhibition hall can be viewed in the “Sponsors and Exhibitors” part from page 78 on.

Exhibitors and SponsorsExhibitors and sponsors may not hold satellite events during the defined “blackout” times unless approved by ENETS. ENETS will strictly enforce this policy.

The blackout times for ENETS 2018, which correspond to the conference program, are as follows:Wednesday, 7 March 08:30 - 13:00 14:00 - 18:15Thursday, 8 March 08:30 - 12:45 14:15 - 17:50Friday, 9 March 08:30 - 12:40 14:10 - 15:40

ENETS also prohibits marketing research and marketing events from being conducted during the Annual Conference. ENETS encourages pharmaceutical companies to observe phRMA guidelines in determining how to interact with delegates at the Annual Conference. Specific questions related to marketing activities should be directed to the ENETS Office in Berlin.

ENETS Annual General AssemblyEvery ENETS member is welcome to attend the Society’s Annual General Assembly Meeting. Entry is restricted to ENETS members only and only members who have paid all their membership fees up to 2018 latest until 15:00 on 8 March 2018 are entitled to vote on any agenda items.

The General Assembly Meeting will be held on Thursday, 8 March at 17:55 in Room 111, First Floor.

General Information

GE

NE

RA

L I

NF

OR

MA

TIO

N

13

Internet / WiFi accessWireless internet access will be available in most areas. SSID: ENETS Password: Barcelona

Conference OrganizationENETS Conference Organization ENETS Officec/o Charité Universitätsmedizin BerlinCampus Virchow-Klinikum Dept. of Hepatology and Gastroenterology Augustenburger Platz 113353 Berlin, Germany

E-mail: info@enets.org

Tel: +49 30 9940 4534 0Fax: +49 30 9940 4534 9

ENETS Conference Website: www.enetsconference.orgENETS Society Website: www.enets.org

General Information

GE

NE

RA

L IN

FO

RM

AT

ION

14

Conference Floor Plan

GE

NE

RA

L I

NF

OR

MA

TIO

N

15

Conference Floor Plan

For full view of all sponsor booths, please refer to page 81

GE

NE

RA

L IN

FO

RM

AT

ION

16

ENETS App

GE

NE

RA

L I

NF

OR

MA

TIO

N

17

ENETS App

SC

IEN

TIF

IC P

RO

GR

AM

18

Bertram WiedenmannGermany

Rocio Garcia-CarboneroSpain

Reza KianmaneshFrance

Dermot O’TooleIreland

Wouter W. de HerderNetherlands

Massimo FalconiItaly

Eva Tiensuu JansonSweden

Martyn CaplinUnited Kingdom

Marianne PavelGermany

Aurel PerrenSwitzerland

Scientific Organizing Committee

SC

IEN

TIF

IC P

RO

GR

AM

19

Professor Gianfranco Delle Fave – MD, PhD,Gianfranco Delle Fave is Professor of Gastroenterology at Sapienza University of Rome, Italy, Specialist in Internal Medicine and Digestive Diseases. At the present, he is also the Scientific Director of the Pancreatic Centre of Rome, President of the Italian Association of Neuroendocrine Tumors (ITANET) and President of the Digestive Diseases Foundation. He is the Italian Delegate of the European Board of Gastroenterology and Hepatology, Member of the Governing Board of ESDO Society, and IAP Association. He has been a Founding Member of ENETS and the Founder of the ENETS Center of Excellence in Rome for Diagnosis and Treatment of NET.

He was also Past President of AISP and SIGE Societies. Due to his expertise, he was a Visiting Professor at several international universities: University of California, UCLA (USA), Saint Louis University (USA), Barts and The London School of Medicine and Dentistry, London (UK), and also a Visiting Scientist and Consultant Physician at NIH Bethesda (USA). He is the author of almost 400 papers and reviews in the most important journals (JCO, NEJM, Lancet Oncology, PNAS, Gastroenterology, Gut) in the fields of Gastroenterology and Oncology, affiliated to the main International Scientific Associations as: AACR, AGA APA ASCO, UEG EPC.)

ENETS Life Achievement Award Laureates and ENETS Honorary Members

2017 Prof. Kjell Öberg SWE

2016 Prof. Jean-Claude Reubi SUI

2015 Dr. Robert T. Jensen USA

2014 Prof. Eric Krenning NED

2013 Dr. Larry Kvols USA

2012 Prof. Steven Lamberts NED

2011 Prof. Jens Rehfeld DEN

2010 Prof. Enrico Solcia ITA

2009 Prof. Rudolf Arnold GER

2008 Prof. Jun Soga JPN

2007 Prof. Lars Grimelius SWE

2006 Dame Julia M. Polak † GBR

2005 Prof. Werner Creutzfeldt † GER

2004 Prof. Michel Mignon FRA

Life Achievement Award

LIFE ACHIEVEMENT AWARD 2018

SC

IEN

TIF

IC P

RO

GR

AM

20

ENETS Committees

ENETS Executive CommitteeMassimo Falconi ITA Chairman Martyn Caplin GBR Vice-Chairman Dermot O’Toole IRL Chairman-Elect Bertram Wiedenmann GER Treasurer Aurel Perren SUI Scientific Secretary Rocio Garcia-Carbonero ESP Member Reza Kianmanesh FRA Member Marianne Pavel GER Member Eva Tiensuu Janson SWE Member

ENETS Advisory Board Detlef Bartsch GEREric Baudin FRALisa Bodei USAIvan Borbath BEL (Registry Representative)Jaume Capdevila ESPJie Chen CHN Frederico Costa BRAAnne Couvelard FRAJaroslaw Ćwikła POLPhilippa Davies GBR (NET Nurse Representative)Wouter W. de Herder NED (Advisory Board Chairman)Gianfranco Delle Fave ITABarbro Eriksson SWEJenny Falkerby SWE (NET Nurse Representative)Nicola Fazio ITADiego Ferone ITAAndrea Frilling GBRSimona Glasberg ISRVera Gorbunova RUS Ashley Grossman GBRRodney Hicks AUSDieter Hörsch GERRobert Jensen USAGregory Kaltsas GREAndreas Kjaer DENUlrich Knigge DENBeata Kos-Kudła POLMatthew Kulke USABruno Niederle AUTEls Nieveen van Dijkum NEDJuan Manuel O’Connor ARGKjell Öberg SWEUlrich-Frank Pape GERAndreas Pascher GERMarc Peeters BELJohn Ramage GBR

SC

IEN

TIF

IC P

RO

GR

AM

21

ENETS Centers of Excellence AuditorsRudolf Arnold GER Günter Klöppel GER Guenter J. Krejs AUT Eric Krenning NED Steven Lamberts NED Kjell Öberg SWE Matthias Rothmund GERBabs Taal NED

ENETS Committees

ENETS Advisory Board continuedEric Raymond FRANicholas Reed GBRGuido Rindi ITA Anja Rinke GERPhilippe Ruszniewski FRARamon Salazar ESPAldo Scarpa ITAJean-Yves Scoazec FRAHalfdan Sorbye NORAnders Sundin SWEChristos Toumpanakis GBRJuan Valle GBRChris Verslype BEL (Registry Representative)Marie-Pierre Vullierme FRAStaffan Welin SWEJames Yao USA

SC

IEN

TIF

IC P

RO

GR

AM

22

Nicholas Reed / Coordinator of the Abstract Reviewing CommitteeProfessor Nicholas Reed has been a consultant Clinical Oncologist at the Beatson Oncology Centre Glasgow, UK, since 1984. In 2012 he was appointed as Honorary Professor in Oncology, University of Glasgow. His main clinical interests lie in thyroid and neuroendocrine cancers and gynaecological cancer. As a result of this he has developed a special interest in the management of rare cancers. He was a founding member, former secretary and later Chairman of the UKINETS (UK & Ireland Neuro-Endocrine Tumour Society), and more recently a member of ENETS and sits on the Advisory Board. He is currently chairman of the ENETS

Annual Conference Scientific Abstracts Committee. He helped to found and foster SCONET bringing together Scottish experts in NET tumors.

ENETS Reviewing Committees

Reviewing Committees 2018

Abstract Reviewing

Abstract Reviewing Coordination: Nicholas Reed GBR

Jaume Capdevila ESPJusto P. Castano ESPAnne Couvelard FRAJaroslaw Ćwikła POL Philippa Davies GBRWouter W. de Herder NEDNicola Fazio ITAAndrea Frilling GBRDavid Gross ISRUlrich-Frank Pape GERStefano Partelli ITA Andreas Pascher GERMarianne Pavel GERMarc Peeters BEL John Ramage GBRGuido Rindi ITAAnja Rinke GERPhillippe Ruszniewski FRAJean-Yves Scoazec FRAHalfdan Sorbye NOR Anders Sundin SWE Christina Thirlwell GBRChristos Toumpanakis GBR

Grant Reviewing

Gianfranco Delle Fave ITAWouter W. de Herder NEDMassimo Falconi ITARocio Garcia-Carbonero ESPSimona Glasberg ISRAshley Grossman GBRDieter Hörsch GERGregory Kaltsas GREReza Kianmanesh FRAUlrich Knigge DENBeata Kos-Kudła POLBruno Niederle AUTEls Nieveen van Dijkum NEDKjell Öberg SWEDermot O’Toole IRLUlrich-Frank Pape GERMarianne Pavel GERGuido Rindi ITA Philippe Ruszniewski FRAAldo Scarpa ITA

SC

IEN

TIF

IC P

RO

GR

AM

23

ENETS Grant Recipients

ENETS CoE Excellence Academy Fellowship Recipients 2017Jorge Barriuso GBRChristodoulos Pipinikas GBR

ENETS CoE Young Investigator Grant Recipient 2018Melissa Frizziero GBR

ENETS Håkan Ahlman Award Recipient 2018Vincenzo Corbo ITA

ENETS Travel Grant Recipients 2018Valentina Andreasi ITAArooj Fatima PAKIvan Kruljac CROFrancesca Muffatti ITASergio Pedraza-Arevalo ESPFrancesca Maria Rizzo GBRTamsin Robb NZLTeresa Sposito GBRAmit Tirosh USAYu Zhang CHN

SC

IEN

TIF

IC P

RO

GR

AM

24

Wednesday, 7 March 201807:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

08:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

09:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

10:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

11:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

12:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

13:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

14:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

15:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

16:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

17:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

18:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

19:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

20:00 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Thursday, 8 March 2018

Nurse Workshop(Additional fee)

07:30 - 08:30 128

LUNCH

12:45 - 14:15 Exhibition area

Session 4B:Basic Science

Abstract Session

14:15 - 15:15 111

Scientific Program Overview

REGISTRATION & COFFEE

08:30 - 09:15 Exhibition area

Interactive Workshops(Additional fee)

07:30 - 08:30 124,125,127

Welcome08:30 - 08:40 113-116 (Plenary)

Session 1:Towards Understanding NET

08:40 - 09:55 113-116 (Plenary)

COFFEE BREAK09:55 - 10:25 Exhibition area

Session 2:Epidemiology

10:25 - 11:25 113-116 (Plenary)

Session 3:Clinical Trials in Progress

11:25 - 12:15 113-116 (Plenary)

Life Achievement Award 201812:15 - 12:35 113-116 (Plenary)

ENETSPostgraduate Course

(Additional fee)

09:15 - 17:10 Room 112

WELCOME RECEPTION

17:15 - 18:15 Foyer, 1st Floor

YOUNG ENETS

18:15 - 18:45 127 & 128

Satellite Symposium IIndustry-Sponsored

12:45 - 14:15 112

Session 4A:Between Bench and Bedside

14:15 - 15:15 113-116 (Plenary)

Poster SessionPoster Walks A

15:20 - 16:05 Exhibition area

Session 5B:Surgery Techniques

16:10 - 17:10 111

Session 5A:Clinical Abstract Session

16:10 - 17:10 113-116 (Plenary)

ENETSGrant Winner Presentations

and Awards Ceremony

17:10 - 17:50 113-116 (Plenary)

ENETSGeneral Assembly

(Members only)

17:55 - 18:50 111

Satellite Symposium IIIndustry-Sponsored

18:50 - 20:20 112

SC

IEN

TIF

IC P

RO

GR

AM

25

Friday, 9 March 2018-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 07:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 08:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 09:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 10:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 11:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 12:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 13:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 14:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 15:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 16:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 17:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 18:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 19:00

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 20:00

ENETS/INCA Symposium

09:35 - 11:30 111

Session 8B:Nurse Session

11:35 - 12:35 111

Scientific Program Overview

Session 6:What’s New in the Field?

08:30 - 09:35 113-116 (Plenary)

Session 7:Cancer and Translational

Biology

09:35 - 10:35 113-116 (Plenary)

Poster SessionPoster Walks B

10:40 - 11:30 Exhibition area

Session 8A:Heterogeneity of NET

11:35 - 12:35 113-116 (Plenary)

LUNCH

12:40 - 14:10 Exhibition area

Session 9:Standards of Care

14:15 - 14:45 113-116 (Plenary)

Session 10:Where Are We Going?

14:45 - 15:35 113-116 (Plenary)

Closing Comment15:35 - 15:40 113-116 (Plenary)

SC

IEN

TIF

IC P

RO

GR

AM

26

ENETS Supported Study

SC

IEN

TIF

IC P

RO

GR

AM

27

8th POSTGRADUATE COURSE: ADVANCES IN NET PRACTICE

Dear Colleagues,

Welcome to the 8th Annual ENETS Postgraduate Course. The aim of this year’s Postgraduate Course is to highlight the advances in GEP and Bronchial NET management and how it applies to your clinical practice.

We are very grateful to our superb expert panel of speakers representing multiple disciplinary fields and the aim is for this to be a relaxed and interactive atmosphere.

We thus ask all participants to please take the opportunity to ask questions as well as meet the speakers during the breaks. Furthermore, your feedback is always valuable in designing future courses and we look forward to receiving your evaluation forms.

Please stay tuned to the PG webcasts and PG webinars after the conference, which will be offered via MY ENETS later in the year.

We hope you enjoy the course.

Best wishes, Martyn Caplin ENETS Vice-Chairman and Course Organizer

Rocio Garcia-Carbonero ENETS Executive Committee Member and Course Organizer

Postgraduate Course Welcome

Rocio Garcia-CarboneroENETS Executive

Committee Member

Martyn CaplinVice-Chairman

SC

IEN

TIF

IC P

RO

GR

AM

28

Wednesday, 7 March 2018

The postgraduate program is designed for clinicians and researchers who wish to learn more and are new to NET diagnosis and therapy (additional fee - limited seats, pre-registration required).Time: 08:30 - 17:10

Time Topic Room

8th ENETS Postgraduate Course 112

08:30 - 09:15 REGISTRATION & COFFEE Exhibition Area

09:15 - 09:30 Opening and Overview 112 Martyn Caplin, GBR

09:30 - 11:15 Postgraduate Course Part 1 112 Chairs: Martyn Caplin, GBR / Kjell Öberg, SWE

09:30 - 09:50 GEP NET Classification: G1 and G2 – How Significant is Tumor Heterogeneity? Jean-Yves Scoazec, FRA

09:50 - 10:10 Endoscopy and EUS: The Role in Gastric, Duodenal, Pancreatic and Rectal NETs Raj Srirajaskanthan, GBR

10:10 - 10:30 Indications and Type of Surgery for Gastric and Duodenal NENs Ulrich Knigge, DEN

10:30 - 10:50 Key Points of Interventional Procedures in Radiology Alban Denys, SUI

10:50 - 11:15 Panel Discussion

11:15 - 11:40 COFFEE BREAK Exhibition Area

11:40 - 13:00 Postgraduate Course Part 2 112 Chairs: Massimo Falconi, ITA / Marianne Pavel, GER

11:40 - 12:00 Familial GEP NET Syndromes – Who Should We Screen and How? Ashley Grossman, GBR

12:00 - 12:20 Familial Case Presentation Gregory Kaltsas, GRE

12:20 - 12:30 Panel Discussion

12:30 - 13:00 New Directions for Bronchial NET Martyn Caplin, GBR

13:00 - 14:00 LUNCH BREAK Exhibition Area

Postgraduate Course Program

SC

IEN

TIF

IC P

RO

GR

AM

29

Wednesday, 7 March 2018

Time Topic Room

14:00 - 15:20 Postgraduate Course Part 3 112 Chairs: Eva Tiensuu Janson, SWE / Bertram Wiedenmann, GER

14:00 - 14:20 Refractory Carcinoid Syndrome and Other Hormonal Syndromes – How to Manage? Wouter W. de Herder, NED

14:20 - 14:40 Preparation for Theatre: Midgut NET, Insulinoma, Phaeochromocytoma David Gross, ISR

14:40 - 14:50 Panel Discussion

14:50 - 15:20 Theranostics for GEP and Bronchial NETs Lisa Bodei, USA

15:20 - 15:40 COFFEE BREAK Exhibition Area

15:40 - 17:00 Postgraduate Course Part 4 112 Chairs: Rocio Garcia-Carbonero, ESP / Philippe Ruszniewski, FRA

15:40 - 16:00 When Do I Choose Chemotherapy Versus Molecular Targeted Agent in G1 and G2 NETs? Rocio Garcia-Carbonero, ESP

16:00 - 16:20 Should All G3 NENs Be Treated the Same? Halfdan Sorbye, NOR

16:20 - 16:50 Case Series Presentations: Unusual Sites of Metastasis: Cardiac, Brain and Orbital Christos Toumpanakis, GBR

16:50 - 17:00 Panel Discussion

17:00 - 17:10 Closing Remarks 112 Martyn Caplin, GBR

17:15 - 18:15 ENETS ANNUAL CONFERENCE WELCOME RECEPTION Foyer in front of 112

18:15 - 18:45 YOUNG ENETS: WELCOME RECEPTION FOR YOUNG INVESTIGATORS 127 & 128 (Invited guests only)

Postgraduate Course Program

SC

IEN

TIF

IC P

RO

GR

AM

30

Poster Walks

Poster Walks will take place within the Poster Sessions on 8 and 9 March in the exhibition hall. The Poster Walks will be identical on 8 and 9 March, all selected Poster Walk Presentations are listed onthe next page. The Poster Walks are offered on a first come, first serve basis and are limited to 15 participants per walk. To join Poster Walk A or B please sign up at the Poster Walk booth (exhibition hall, poster area).

Thursday, 8 March | 15:20 - 16:05 | POSTER WALKS A Room: Exhibition hall, poster area

15:20 - 16:05 POSTER WALK A – BASIC SCIENCE (Poster Walk Lead: Christina Thirlwell, GBR)

15:20 - 16:05 POSTER WALK A – CLINICAL (Poster Walk Lead: Christos Toumpanakis, GBR)

Friday, 9 March | 10:40 - 11:30 | POSTER WALKS BRoom: Exhibition hall, poster area

10:40 - 11:30 POSTER WALK B – BASIC SCIENCE (Poster Walk Lead: Anne Couvelard, FRA)

10:40 - 11:30 POSTER WALK B – CLINICAL (Poster Walk Lead: Wouter W. de Herder, NED)

SC

IEN

TIF

IC P

RO

GR

AM

31

Poster Walks

SELECTED POSTERS – BASIC SCIENCE – FOR POSTER WALK A AND B

A17 Rene Pschowski GER Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Receptor Expression in Patients with Neuroendocrine NeoplasiaA18 Apostolos Tsolakis SWE Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?B04 Jerome Cros FRA Genomic and Transcriptomic Characterization of Aggressive Well Differentiated Pancreatic Neuroendocrine Tumors (WD PanNET).B12 Jerena Manoharan GER Chemoprevention with Enalapril and Aspirin in Men1(+/T) Knockout Mouse ModelC01 Anela Blazevic NED The Effect of Temozolomide on Pancreatic Neuroendocrine Tumours in Vitro and Role of MGMT and MMR System in Temozolomide Resistance. C05 Aura Dulcinea Herrera-Martinez NED Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell CultureC13 Teresa Sposito GBR Histone Replacement in Cancer: Dissecting the Role of H3.3 Chaperones in Pancreatic Tumorigenesis

SELECTED POSTERS – CLINICAL – FOR POSTER WALK A AND B

G01 Antwi Antwi SUI Comparison of Glucagon-Like-Peptide-1 (GLP-1) Receptor PET/CT, SPECT/CT and 3T MRI for the Localisation of Insulinomas: Evaluation of Accuracy in a Prospective Crossover Imaging Study.H17 Faidon Laskaratos GBR Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumours (NETs)I01 Arvind Dasari USA A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine TumorsI05 Jennifer Chan USA Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine TumorsK02 Else Aalbersberg NED Parameters to Predict Overall Survival after PRRT – A Multivariate Analysis in 783 PatientsL02 Nicole Brighi ITA Morphological Factors Related to Nodal Metastases in Neuroendocrine Neoplasms of the Appendix. A Multicenter Retrospective Study.M09 Mark Kidd USA Validation of a Blood-Based Biomarker Test for the Diagnosis and Management of Bronchopulmonary Neuroendocrine Tumors

SC

IEN

TIF

IC P

RO

GR

AM

32

Thursday, 8 March 2018 Time Topic Room

07:30 - 08:30 Nurse Workshop and Interactive Workshops are parallel sessions

07:30 - 08:30 Nurse Workshop: Carcinoid Crisis and Carcinoid Heart Disease 128 (Additional fee - pre-registration required)

07:30 - 07:35 Introduction Catherine Bouvier, FRA

07:35 - 07:45 Carcinoid Heart Disease Wanda Geilvoet, NED

07:45 - 07:55 Carcinoid Crisis Deborah Pitfield, GBR

07:55 - 08:30 Group Work and Discussion

07:30 - 08:30 Interactive Workshops 124, 125, 127 (Additional fee - pre-registration required)

Workshop 1: Gastroenterologist and Nuclear Medicine View 124 Functional Imaging and PRRT Treatment – When and How Often Is It Really Needed? Elettra Merola, GER / Vikas Prasad, GER

Workshop 2: Gastroenterologist and Surgeons View 125 Management of Gastric Neuroendocrine Neoplasms Ulrich Knigge, DEN / Philippe Ruszniewski, FRA

Workshop 3: Endocrinologist and Cardiologists View 127 Management of Carcinoid Syndrome and Carcinoid Heart Disease Joseph Davar, GBR / Simona Glasberg, ISR

08:30 - 08:40 Welcome 113-116 (Plenary) Massimo Falconi, ITA

08:40 - 09:55 Session 1: Towards Understanding NET 113-116 (Plenary) Chairs: Jaume Capdevila / Guido Rindi, ITA

08:40 - 09:05 The Genetic Landscape of PanNENs Aldo Scarpa, ITA

09:05 - 09:30 Angiogenesis in NET – Where Are We Now? James Yao, USA

09:30 - 09:55 Neuroendocrine Transformation of Adenocarcinoma as Exemplified by Prostate Cancer? Mark A. Rubin, SUI

09:55 - 10:25 COFFEE BREAK Exhibition area

Scientific Program

SC

IEN

TIF

IC P

RO

GR

AM

33

Scientific Program

Thursday, 8 March 2018 Time Topic Room

10:25 - 11:25 Session 2: Epidemiology – ENETS Meets East and West 113-116 (Plenary) Chairs: Jie Chen, CHN / Staffan Welin, SWE

10:25 - 10:40 SEER Data Michelle Kim, USA

10:40 - 10:55 Asian-Pacific David Wyld, AUS

10:55 - 11:10 European Côme Lepage, FRA

11:10 - 11:25 Panel Discussion

11:25 - 12:15 Session 3: Clinical Trials in Progress 113-116 (Plenary) Chairs: Diego Ferone, ITA / Gregory Kaltsas, GRE

11:25 - 11:40 Somatostatin Receptor Targeting and Combinations Guillaume Nicolas, SUI

11:40 - 11:55 Targeted Therapy and Chemotherapy / Immunotherapy Enrique Grande, ESP

11:55 - 12:05 Discussion

12:05 - 12:15 Presidential Abstract: PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastro-Entero- Pancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort Wouter van der Zwan, NED

12:15 - 12:35 Life Achievement Award 2018 113-116 (Plenary) Chair: Massimo Falconi, ITA

12:15 - 12:20 Dedication Bertram Wiedenmann, GER

12:20 - 12:35 Recipient and Keynote Presentation: From Gut Hormones to Intestinal Neuroendocrine Tumors Gianfranco Delle Fave, ITA

Satellite Symposium and Lunch take place at the same time

12:45 - 14:15 Satellite Symposium I, Industry-Sponsored 112

For symposium participants lunch boxes will be available in room 112.

12:45 - 14:15 LUNCH BREAK Exhibition area

SC

IEN

TIF

IC P

RO

GR

AM

34

Scientific Program

Thursday, 8 March 2018 Time Topic Room

Session 4A and Session 4B are parallel sessions

14:15 - 15:15 Session 4A: Between Bench and Bedside 113-116 (Plenary) Chairs: David Gross, ISR / Ashley Grossman, GBR

14:15 - 14:27 Stromal Immune Contexture Predicts Disease-Free Survival in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs) Massimo Milione, ITA

14:27 - 14:39 Systematic Evaluation of the Immune Microenvironment of Neuroendocrine Tumors (NET) Clare Vesely, GBR

14:39 - 14:51 Using Adult Stem-Cell Derived Organoids to Model Neuroendocrine Tumor Growth Talya Dayton, NED

14:51 - 15:03 Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors Timon Vandamme, BEL

15:03 - 15:15 Genome-Wide DNA Methylation Profiling of Pancreatic Neuroendocrine Tumors Gitta Boons, BEL

14:15 - 15:15 Session 4B: Basic Science Abstract Session 111 Chairs: Ramon Salazar, ESP / Jean-Yves Scoazec, FRA

14:15 - 14:27 Presidential Abstract: Epigenetic Changes in DAXX and/or ATRX Negative Pancreatic Neuroendocrine Tumors Annunziata Di Domenico, SUI

14:27 - 14:39 Genetic Analysis Identifies Subgroups of Small Well-Differentiated Pancreatic Neuroendocrine Tumors with Different Risk for Liver Metastases Antonio Pea, ITA

14:39 - 14:51 BRAF-V600E Driven Mutations in Grade 3 Neuroendocrine Carcinomas of Colon Origin: Results from Genomic/Epigenomic Profilings and Patient-Derived Mouse Model Jaume Capdevila, ESP

SC

IEN

TIF

IC P

RO

GR

AM

35

Scientific Program

Thursday, 8 March 2018 Time Topic Room

14:51 - 15:03 Mitochondrial or Aerobic Glycolysis Oriented Metabolism May Define Pancreatic Neuroendocrine Tumors (PanNET) Resistance to mTOR-Targeting Therapies Jerome Cros, FRA

15:03 - 15:15 miRNA Expression Defines Novel Subgroups of Small Intestinal Neuroendocrine Tumors Yvonne Arvidsson, SWE

15:20 - 16:05 Poster Session and Poster Walks A Exhibition area Coffee break is included in the Poster Session

Session 5A and Session 5B are parallel sessions

16:10 - 17:10 Session 5A: Clinical Abstract Session 113-116 (Plenary) Chairs: Barbro Eriksson, SWE / Anja Rinke, GER

16:10 - 16:20 The ENETS Registry: First Results of a Collaborative Effort Including over 12.000 Patients with Neuroendocrine Neoplasms (NENs) from 7 European Countries Ivan Borbath, BEL

16:20 - 16:30 Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients’ Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study Angela Lamarca, GBR

16:30 - 16:40 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors Jonathan Strosberg, USA

16:40 - 16:50 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations Anguraj Sadanandam, GBR

16:50 - 17:00 Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms: A Retrospective International Multicenter Study Halfdan Sorbye, NOR

17:00 - 17:10 PD-L1 Expression and Its Clinical Relevance in Neuroendocrine Tumors of the Lung Atsuko Kasajima, GER

SC

IEN

TIF

IC P

RO

GR

AM

36

Scientific Program

Thursday, 8 March 2018 Time Topic Room

16:10 - 17:10 Session 5B: Surgery Techniques 111 Chairs: Detlef Bartsch, GER / Bruno Niederle, AUT

16:10 - 16:30 The Place for Adjuvant and Neoadjuvant Treatment in NET

16:10 - 16:20 Surgical Perspectives Andreas Pascher, GER

16:20 - 16:30 Oncological Perspectives Nicola Fazio, ITA

16:30 - 16:45 What Extent of Lymphadenectomy for PNETs? Stefano Partelli, ITA

16:45 - 17:00 What Extent of Lymphadenectomy for SINETs? Reza Kianmanesh, FRA

17:00 - 17:10 Panel Discussion

17:10 - 17:50 Grant Winner Presentations and Awards Ceremony 113-116 (Plenary) Chair: Massimo Falconi, ITA

17:10 - 17:13 CoE Excellence Academy Fellowship 2017 Jorge Barriuso, GBR

17:13 - 17:16 CoE Excellence Academy Fellowship 2017 Christodoulos Pipinikas, GBR

17:16 - 17:19 CoE Excellence Academy Fellowship 2017 – Update Elettra Merola, GER

17:19 - 17:22 CoE Excellence Academy Fellowship 2017 – Update Mauro Cives, ITA

17:22 - 17:25 CoE Young Investigator Grant 2017 – Update Alexa Childs, GBR

17:25 - 17:28 CoE Young Investigator Grant 2016 – Update Joakim Crona, SWE

17:28 - 17:31 ENETS Translational Medicine Fellowship 2017 – Update Gianfranca Corna, ITA

17:31 - 17:50 Awards Ceremony

17:55 - 18:50 ENETS General Assembly (Members only) 111

18:50 - 20:20 Satellite Symposium II, Industry-Sponsored 112

SC

IEN

TIF

IC P

RO

GR

AM

37

Scientific Program

Friday, 9 March 2018 Time Topic Room

08:30 - 09:35 Session 6: What’s New in the Field? 13-116 (Plenary) Chairs: Anne Couvelard, FRA / Marc Peeters, BEL

08:30 - 08:50 The Pathology Perspective Marco Volante, ITA

08:50 - 09:10 The Biomarker Perspective Eva Tiensuu Janson, SWE

09:10 - 09:30 Overview of Best Clinical and Basic Abstracts Robert Jensen, USA

09:30 - 09:35 Discussion

Session 7, Poster Walks B and Symposium are parallel sessions

09:35 - 10:35 Session 7: Cancer and Translational Biology 113-116 (Plenary) Chairs: Eric Raymond, FRA / Bertram Wiedenmann, GER

09:35 - 09:55 Microbes, Microbiota and Cancer Julia Drewes, USA

09:55 - 10:15 Epigenetics and Potential Drug Pathways for BP- and GEP-NETs Christina Thirlwell, GBR

10:15 - 10:35 Genetic Profiling of NET/NEC Stefan Fröhling, GER

10:40 - 11:30 Poster Session and Poster Walks B Exhibition area Coffee break is included in the Poster Session

09:35 - 11:30 ENETS/INCA Symposium: Unmet Needs of NET Patients – 111 From Identification to Action Chairs: Martyn Caplin, GBR / Ron Hollander, USA

A Joint Effort by NET Patient and Medical Leaders to Identify and Address Issues That Impede Optimal Care and Research

09:35 - 09:40 Welcome and Introductions from ENETS/INCA Martyn Caplin, GBR / Ron Hollander, USA

09:40 - 09:50 Unmet Needs in NETs, a Global Dialogue: WNCD Brings “Unmet Needs” to Millions Worldwide Simone Leyden, AUS

09:50 - 10:50 The “Patient Pathway”: Providing Patients with Timely and Valid Information and Access to Optimal Treatment

09:50 - 10:00 The “Patient Pathway”: Ensuring All Patients Get the Information and Services They Need for Optimal Care Martyn Caplin, GBR

SC

IEN

TIF

IC P

RO

GR

AM

38

Scientific Program

Friday, 9 March 2018 Time Topic Room

10:00 - 10:08 Survey Results Identifying Needs: Patient Information and Access to NET Centers and Treatments Teodora Kolarova, BUL

10:08 - 10:33 Information to Patients: Critical Elements – From the Nurse Specialists’ and Patients’ Perspective Lise Munk Plum, DEN / Dirk Van Genechten, BEL / Kate Wakelin, AUS

10:33 - 10:50 Panel Discussion: Addressing the Needs – Medical and Patient Advocate Leaders Discuss Priority Joint Actions Martyn Caplin, GBR / Paul Coffey, GBR / Lise Munk Plum, DEN / Dirk Van Genechten, BEL / Kate Wakelin, AUS

10:50 - 11:30 Advancing Research for Better Treatments and Cures: NET Patient and Medical Society Partnerships in Setting Priorities, Advancing Clinical Trials, Advocacy for Research Funding

10:50 - 11:00 Survey Results Identifying Needs: Research Priorities, Clinical Trials, Need for Funding Ron Hollander, USA

11:00 - 11:20 Patient Engagement in Research Ben Lawrence, NZL / Josh Mailman, USA

11:20 - 11:30 Panel Discussion: Addressing the Needs - Medical and Patient Advocate Leaders Discuss Action Plan to Address Priority Issues Ron Hollander, USA / Teodora Kolarova, BUL / Ben Lawrence, NZL / Simone Leyden, USA / Josh Mailman, USA

Session 8A and Session 8B are parallel sessions

11:35 - 12:35 Session 8A: Heterogeneity of NET 113-116 (Plenary) Chairs: Marianne Pavel, GER / Simron Singh, CAN

11:35 - 11:45 Introduction Marianne Pavel, GER

11:45 - 11:55 Clinical Case Lung Eric Baudin, FRA

11:55 - 12:10 Interdisciplinary Discussion Wouter W. de Herder, NED / Andrea Frilling, GBR / Mauro Giulio Papotti, ITA / Christos Toumpanakis, GBR / Damian Wild, SUI

SC

IEN

TIF

IC P

RO

GR

AM

39

Scientific Program

Friday, 9 March 2018 Time Topic Room

12:10 - 12:20 Clinical Case PanNET Juan Valle, GBR

12:20 - 12:35 Interdisciplinary Discussion Wouter W. de Herder, NED / Andrea Frilling, GBR Mauro Giulio Papotti, ITA / Christos Toumpanakis, GBR Damian Wild, SUI

11:35 - 12:35 Session 8B: Nurse Session 111 Chairs: Paul Coffey, GBR / Lise Munk Plum, DEN / Bertram Wiedenmann, GER

11:35 - 12:05 Patient Reported Needs

11:35 - 11:45 Nutritional Status and Nutritional Risk in Patients with Neuroendocrine Tumors Mette Borre, DEN

11:45 - 11:55 Self-Reported Side Effects in Neuroendocrine Tumour (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses Tara Whyand, GBR

11:55 - 12:05 Questions & Answers

12:05 - 12:35 Nurse in Practice

12:05 - 12:15 Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti-Cancer Agents (SACTs) Philippa Davies, GBR

12:15 - 12:25 Current Educational Strategies Used by Nurses Caring for NET Patients: An Electronic Survey Across 25 Countries Catherine Bouvier, GBR

12:25 - 12:35 Questions & Answers

12:40 - 14:10 LUNCH BREAK Exhibition area

14:15 - 14:45 Session 9: Standards of Care for Merkel Cell Carcinoma 113-116 (Plenary) Chairs: Vera Gorbunova, RUS / Tim Meyer, GBR

14:15 - 14:35 From Biology to Therapy Jürgen Becker, GER

14:35 - 14:45 Open Discussion

SC

IEN

TIF

IC P

RO

GR

AM

40

Scientific Program

Friday, 9 March 2018 Time Topic Room

14:45 - 15:35 Session 10: Where Are We Going? 113-116 (Plenary) Chairs: Beata Kos-Kudła, POL / Kjell Öberg, SWE

14:45 - 15:05 NETomic Analysis Based Liquid Biopsy: Beyond the Seven Bridges of Konigsberg Irvin Modlin, USA

15:05 - 15:25 Macrodata Management Andrea Califano, USA

15:25 - 15:35 Discussion

15:35 - 15:40 Closing Comment 113-116 (Plenary) Dermot O’Toole, IRL

SC

IEN

TIF

IC P

RO

GR

AM

41

ENETS Supported Study

SC

IEN

TIF

IC P

RO

GR

AM

42

Barriuso, Jorge – MD, PhD / Grant Winner Presentations Dr. Jorge Barriuso completed his residency program in Medical Oncology at Hospital Universitario La Paz (Madrid, Spain) in 2005. Then, he obtained a “Rio Hortega” Junior Research contract and presented his PhD in May 2007. In 2008, he was a clinical research fellow at the Royal Marsden Hospital Drug Development Unit, London, UK. He has a special interest in gastro-intestinal malignancies, hepato-pancreato-biliary cancers, neuroendocrine tumors and drug development. In 2013, he moved to the University of Manchester to build new animal models in these malignancies and being involved in clinical research at The Christie NHS Foundation

Trust. Dr. Barriuso has published more than 50 peer-reviewed articles and more than 20 book chapters.

Bartsch, Detlef Klaus – MD, Professor / Session 5BDetlef K. Bartsch is Professor and Chairman of the Department of Visceral-, Thoracic- and Vascular Surgery at the Philipps-University Marburg, Germany. He has 25 years of experience in the whole field of endocrine and pancreatic surgery, especially in GEP-NETs and MEN1. He is the surgical partner of the ENETS Center of Excellence at the Marburg University hospital. He was President of the German Society of Endocrine Surgeons from 2014-2017. He has published over 230 publications in peer-reviewed journals and is member of the ENETS Advisory Board.

Baudin, Eric – MD, PhD, Professor / Session 8A Eric Baudin is Assistant Professor at Gustave Roussy (University of Paris-Sud) where he chairs the Endocrine Tumor Board. He is also co-chair of the French Network for Adrenal Cancer (COMETE) and scientific coordinator of the French Network of Neuroendocrine Tumors (GTE-RENATEN). He served as member of the ENSAT, PRESSOR and ENETS associations. His main field of interest are endocrine tumors. He is involved in many subjects, including prognostic stratification, treatment with radioactive isotopes, chemotherapy and molecular targeted therapy, but also biomarker development. He has been investigator for most prospective

clinical trials on endocrine tumors. He has published more than 150 original articles in the field of endocrine tumors and has received awards from the French Academy of Medicine and of Sciences.

Becker, Jürgen – MD, PhD, Professor / Session 9 Jürgen Becker was trained in Dermatology at the University of Würzburg as well as in Tumor Immunology at the Scripps Research Institute, La Jolla, CA, USA, and the Danish Cancer Society, Copenhagen. 2003 he became full professor for Dermato-Oncology at Würzburg, where he coordinated a Clinical Research Group focusing on the tumor microenvironment. 2010 he was appointed as Director of General Dermatology at the Medical University of Graz, Austria, where he coordinated the FP7 EU-project IMMOMEC (IMmune MOdulating strategies for treatment of MErkel cell Carcinoma, www.immomec.eu) and served as deputy speaker of the graduate

program MOLecular fundamentals of INflammation (www.medunigraz.at/DK-MOLIN/). 2014 he joined the German Cancer Consortium as Head of the Institute for Translational Skin Cancer Research at the University Hospital Essen, Germany (www.unidue.de/zmb/members/becker/).

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

43

Bodei, Lisa – MD, PhD / ENETS Postgraduate CourseDr. Bodei graduated and earned her MD degree in 1995 from the Medical University of Pisa, where she was a Resident in Nuclear Medicine until 1999. In 2009, she was awarded a PhD from the Department of Nuclear Medicine and Molecular Imaging, University of Groningen, the Netherlands, for her work in peptide receptor radionuclide therapy using somatostatin analogues. Her main research interests are theranostics, particularly receptor radionuclide therapy with somatostatin, bombesin and PSMA analogues for diagnosis and therapy, and translational research applied to radiopeptide therapy of neuroendocrine tumors. She has authored more than

100 articles in international peer-reviewed journals and published eight invited book chapters, and is currently a member and reviewer for numerous journals, including JNM, EJNMMI, QJNM, Neuroendocrinology and Clinical Cancer Research. She has given numerous lectures at national and international meetings and has served on many committees at an executive level.

Borre, Mette – RD / Nurse SessionMette Borre is clinical dietician at Department of Hepatology and Gastroenterology, ENETS Centre of Excellence, Aarhus University Hospital, Denmark. She is also a teacher at VIA University College and adviser for the Danish National Board of Health, Panel for acceptance of nutritional supplements and tube feeding. She has a special interest in the nutritional treatment of patients with neuroendocrine tumors (s. Borre et al., Nutritional status and nutritional risk in patients with neuroendocrine tumors. Scandinavian Journal of Gastroenterology. 2018).

Bouvier, Catherine / Nurse Workshop, Nurse SessionCatherine Bouvier is the CEO and co-founder of the UK organization The NET Patient Foundation (NPF). She started work as a NET CNS at the Royal Free Hospital (London) in 1999, and was there for 7 years until she moved into community advocacy in 2008. Since 2008 she has focused on developing and growing the services provided by the NPF. The NPF has a vision of a world in which people know how to recognize, diagnose, treat, care for, and ultimately, cure patients with neuroendocrine cancer, and a purpose to support and inform patients and families from diagnosis, enabling access to the best care and treatment, whilst stimulating

neuroendocrine cancer research, increasing national awareness and influencing improvements in outcomes.

Califano, Andrea – MD, PhD, Professor / Session 10Andrea Califano is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics. The Califano Lab uses a combination of computational and experimental methodologies to reconstruct the regulatory logic of human cells in genome-wide fashion to identify master regulator

proteins responsible for human disease, including cancer and neurodegenerative syndromes.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

44

Capdevila, Jaume – MD, PhD / Session 1Jaume Capdevila serves as medical oncologist and clinical and translational researcher at Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain. He is also leading the Gastrointestinal and Endocrine Tumor Unit at Teknon Cancer Institute. He is involved in research and treatment of patients with gastrointestinal cancer and endocrine tumors as well as in early-drug development. He has published over 90 articles in peer-reviewed journals. He is an active member of several oncology societies and actively participates in national and international trials.

Caplin, Martyn – BSc Hons, DM, FRCP, Professor / ENETS Postgraduate Course, ENETS/INCA SymposiumMartyn Caplin is Professor of Gastroenterology & GI Neuroendocrinology at the Royal Free Hospital and University College London. He has been with ENETS since its foundation in 2004. He was its Chairman (2014-2016) and Vice-Chairman (2016-2018). He also leads The Royal Free Hospital’s ENETS’ CoE and both scientific and clinical research programs on neuroendocrine tumors. He is a founderand Past-Chairman of the UK & Ireland Neuroendocrine Tumour Society (UKINETS). In recognition of his clinical leadership and research in the field of NETs he has

received a Lifetime Achievement Award from the UKINETS. 2006-2014 he was a member of the National Cancer Research Institute (NCRI) Upper-G.I. Cancer Committee and he is Immediate Past-Chairman of the NCRI Neuroendocrine Tumour group. He has published over 150 peer review papers, written multiple book chapters and co-authored two books. He regularly lectures both nationally and internationally. 2006-2012 he was the clinical lead for “NHS Evidence” for Gastroenterology and Liver diseases (under the auspices of NICE), chairing annual evidence updates into gastrointestinal and liver disorders.

Chen, Jie – MD, PhD, Professor / Session 2Professor Jie Chen is Deputy Director of the Department of Gastroenterology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. Her main area of interest are digestive neuroendocrine tumors. As one of the pioneer expert for NETs in China, she devotes her attention on clinical and translational research of GEP-NETs. She founded the first Multidisciplinary Care Team for NETs in China in 2011 and the Chinese Study Group for Neuroendocrine Tumors (CSNET) in 2015. She is currently the Chair of CSNET. Her major areas of research interest are the therapeutic strategies of NETs and the development of biomarkers of diagnostic or

therapeutic interest in NETs. She has published high quality peer review papers in NETs field during the past seven years. She joined the ENETS Advisory Board in 2015.

Childs, Alexa – MD, MB, BChir, MRCP / Grant Winner Presentations Alexa Childs is a Clinical Research Fellow at UCL Cancer Institute and Medical Oncology trainee at the Royal Free Hospital, London. Working within Professor Tim Meyer’s lab, her research focuses on the characterization of circulating tumor cells derived from patients with neuroendocrine tumors. She was awarded the ENETS CoE Young Investigator Grant (2017) and took part in the 1st ENETS CoE Excellence Academy Fellowship (EEAF) Meeting, Munich, 2017.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

45

Cives, Mauro – MD / Grant Winner Presentations Dr. Mauro Cives obtained his medical degree from the University of Bari, Italy. He completed his fellowship in Medical Oncology over the same institution in 2014 under the mentorship of Prof. Franco Silvestris. 2013 - 2016 Dr. Cives worked as Research Associate with Prof. Jonathan Strosberg at the Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Currently, he is Assistant Professor of Medical Oncology in the Department of Biomedical Sciences and Human Oncology, University of Bari, Italy. Dr. Cives’ work focuses on the identification of pathobiological mechanisms driving bone colonization in NETs as well as on the

preclinical and clinical evaluation of innovative treatments for NETs. In 2017, Dr. Cives was awarded with the ENETS CoE Excellence Academy Fellowship (2017) for the project “CAR-T cells for GEP-NETs”.

Coffey, Paul / Nurse SessionPaul Coffey was a general practitioner for thirty-six years till his operation because of a pancreatic NET. Now he attends the Oxford ‘NET Natter’ bi-monthly meetings, at which he volunteers to attend as a patient representative. He co-edited ‘Management of Low Back Pain in Primary’ Care’ in 2001 and was the Royal College of GP’s representative on the NICE Guideline Committee on Chronic Back Pain. He also sat on several local medical committees.

Corna, Gianfranca – MD, PhD / Grant Winner Presentations Gianfranca Corna is a Senior Post-Doc in the lab of Vincenzo Russo at San Raffaele Scientific Institute in Milan, Italy. Her main interest is studying the role of oxysterols in pancreatic neuroendocrine tumors. She was awarded the ENETS Translational Medicine Fellowship 2017 and took part in the 1st ENETS CoE Excellence Academy Fellowship Meeting, Munich, 2017.

Couvelard, Anne – MD, PhD, Professor / Session 6Anne Couvelard is Professor of Pathology at University of Paris Diderot and Head of the Department of Pathology located in Beaujon and Bichat Hospitals, Paris, France. Her main topics of research are pancreatic and neuroendocrine oncogenesis and the relationship between tumor progression, pathology and genetics. ENETS member since 2004, ENETS Advisory Board member since 2015, elected at the board of the French Neuroendocrine Tumor Group (GTE) in 2010 and member of the French Pathological Network for Neuroendocrine Tumors “TENpath” since 2011, she was involved in the 2017 WHO classification of endocrine organs. She

has published more than 250 papers in international journals and is a reviewer for journal in the fields of pathology, oncology gastroenterology and endocrinology.

Crona, Joakim – MD, PhD / Grant Winner Presentations Joakim Crona is researcher and resident in Clinical Oncology affiliated to the Department of Endocrine Oncology, Uppsala, Sweden. His current research focuses on “How we can use information on disease biology to improve outcome of patients with neuroendocrine tumors?”. He has been awarded with the ENETS CoE Young Investigator Grant 2016 for a project on clinical and molecular evolution of neuroendocrine tumors.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

46

Ćwikła, Jaroslaw B. – MD, Professor / Session 8ADr. Jaroslaw B. Ćwikła is Associate Professor at the University of Warmia and Mazury, Olsztyn, Poland, and qualified in Medicine from Warsaw Medical Academy. He trained in Diagnostic Imaging in Olsztyn and Medical Centre of Postgraduate Education (CMKP), Warsaw. During this time he subsequently trained in Nuclear Medicine, received diploma in 1997 and in Radiology in 2001. He has been Consultant in Nuclear Medicine in Warsaw. In 1996 and 2000 he was a research fellow in Royal Free Hospital, London, UK, mainly involved in clinical research of general nuclear medicine and NET. He is a pioneer, in intra-arterial PRRT and he

introduced radioembolisation (RE) in Poland. Since 2005, he has been a leader of the Patients Group with NEN in Poland. He has published 125 scientific papers, 12 book chapters and 250 abstracts. His scientific work concentrates on diagnosis, therapy and clinical follow-up of NEN.

Davar, Joseph – MD, PhD, FRCP, FACC / Interactive Workshop 3Dr. Joseph Davar is a Consultant Cardiologist at the Royal Free Hospital (RFH) and Honorary Senior Lecturer at UCL, London, UK. He leads Valvular Heart Disease and Carcinoid HD as well as Cardiac CT programs at the RFH. He leads an active research program, has numerous publications in peer reviewed journals and regularly lectures nationally and internationally. Dr. Davars main interest is non-invasive diagnosis and management of different cardiac pathologies including valvular heart disease, carcinoid heart disease, and chemotherapy induced cardiomyopathies.

Davies, Philippa – RN, BN, MA / Nurse SessionPhilippa Davies currently works as a Senior Matron for Oncology/Haematology at the Royal Free London NHS foundation Trust, an ENETS Centre of Excellence for Neuroendocrine Tumors. She has worked within the Neuroendocrine Tumor Unit for over 12 Years, initially as a nurse specialist and then as Lead Nurse. She currently runs a nurse-led systemic anti-cancer therapy (SACT) prescribing clinic for NET patients. She has completed her master degree and is a nurse prescriber. She is the nurse adviser for the UK national charity for NETs, the NET Patient Foundation. She is passionate about improving the educational support for nurses

caring for NET patients both within the UK and across Europe. She is Vice Chair of the ENETs Nurse Group which actively encourages nurse-led research projects within the UK and Europe.

de Herder, Wouter W. - MD, PhD, Professor / ENETS Postgraduate Course, Session 8AWouter W. de Herder is Professor of Endocrine Oncology at the Erasmus MC, Rotterdam, the Netherlands. He is Chairman of a Multidisciplinary Group for Endocrine Oncology at the Erasmus MC and Head of the ENETS CoE for Neuroendocrine Tumors. His major research interests are neuroendocrine and endocrine tumors. 2009–2014 he served as a Board Member of the Dutch Society for Endocrinology (NVE) and as Chairman (2006-2008) as well as Vice-Chairman (2008-2010) of the ENETS. He is member of the Advisory Boards of ENETS

and NANETS and served as Local Organizing Committee (LOC) Chair of the 13th European Congress of Endocrinology (ECE2011) in Rotterdam, the Netherlands. He is a member of the editorial boards of PLoS ONE, Neuroendocrinology, Endocrinology, Diabetes & Metabolism Case Reports, Clinical Endocrinology and Endocrine-related Cancer. He is a member of the Publishing and Communications Committee of the ESE and Editor of ESE News. Professor de Herder has given >150 invited presentations at Dutch national and international meetings.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

47

Denys, Alban – Professor / ENETS Postgraduate CourseProfessor Alban Denys is interventional radiologist in CHUV, University of Lausanne, Switzerland. Trained in France (Hopital Beaujon, Paris, VII University) and in Montreal (Université de Montréal), he moved to Lausanne in 1999. He authored 193 articles in peer reviewed journals. His main interests are the development of new therapeutic strategies for primary and secondary liver tumors including the development and patent of embolization particles loaded with targeted therapies and the clinical evaluation of ablation devices. Professor Alban Denys is board member of the recently created SIO Society of Interventional Oncology and is the

future Chairman of the ECIO (European Conference of Interventional Oncology).

Drewes, Julia – MD, PhD / Session 7 Dr. Drewes has studied the interactions between various microbes and the immune response for over 10 years. Dr. Drewes completed a PhD at Johns Hopkins with Dr. Christine Zink, focusing on the immunosuppressive pathways regulated by IDO and PD1/PDL1 during HIV and SIV infection, pathways also critical to immunotherapy in cancer. In 2014 she transitioned to a postdoctoral fellowship in the laboratory of Dr. Cynthia Sears with co-mentorship from Drew Pardoll at the Bloomberg-Kimmel Institute for Immunotherapy at Johns Hopkins. Her current projects include work on bacterial biofilm-mediated carcinogenesis in colorectal cancer as well as fecal

microbiota transplant therapy for pediatric patients with recurrent C. difficile.

Eriksson, Barbro – MD, PhD, Professor / Session 5ABarbro Eriksson is Professor and Senior Consultant of Endocrine Oncology and former Head of the Department of Endocrine Oncology and ENETS Centre of Excellence at Uppsala University Hospital, Sweden. After obtaining her medical degree at Uppsala University in 1978, she went on to complete residencies in Oncology in 1988, Endocrinology in 1989 and Internal Medicine in 1993 at Uppsala University Hospital. Professor Eriksson´s main research interests have been diagnostic procedures, including positron emission tomography (PET) with specific tracers for neuroendocrine tumors (5-HTP, 68Ga-labelled somatostatin analogs,

GLP-1R) and development of new therapeutic agents for these tumors, including temozolomide (introduced it in 1999), interferon, somatostatin analogs, molecular targeted agents and PRRT in neuroendocrine neoplasms. She was one of the founding members of ENETS and is now a member of the ENETS Advisory Board and other societies, including the Swedish Medical Society, ESMO and ASCO. She is also reviewer for several journals, including JCEM, Neuroendocrinology, Endocrine-Related Cancer, Lancet Oncology, Lancet Diabetes and Endocrinology and the co-author of more than 257 articles of which 202 are original articles.

Falconi, Massimo – MD, Professor / Grant Winner Presentations, Life Achievement Award 2018Professor Massimo Falconi is currently Full Professor of Surgery and Chairman of the Pancreatic Unit at the University Vita e Salute, San Raffaele Hospital IRCCS, in Milan, Italy. In addition to his position as the Chairman of ENETS (2016 – 2018), he is a member of IAP, EPC and EAHPBA. He serves as Associate Editor for the section of the pancreas and neuroendocrine tumors for Digestive and Liver Disease. He is also editorial member of World Journal of Gastroenterology, subject Area Editor of The International Journal of Biological Markers and of International Journal of

Endocrine Oncology. Since 2018 he is in the Scientific Committee of Lancet Oncology. He has written almost 400 peer-reviewed articles. Prof. Falconi studied medicine at the University of Verona, specializing in general surgery, gastroenterology and endoscopy. He has participated in numerous international medical research projects.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

48

Fazio, Nicola – MD, PhD / Session 5B Nicola Fazio graduated at the University of L’Aquila, Italy, Faculty of Medicine and Surgery, in 1988. He specialized in Internal Medicine, in L’Aquila, in 1993, and then in Oncology, in Milan, in 2003. In 2013 he received his PhD in Digestive Oncology. Currently he is Director of the Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors at the European Institute of Oncology, where he has been working since 1995. Since 2015 he is head of the IEO ENETS Center of Excellence for GEP NETs. He is ESMO Faculty Coordinator for Neuroendocrine, Endocrine and CUP for the period 2016-2019. Since 2013 he is coordinator of Italian (AIOM/

ITANET) neuroendocrine neoplasms guidelines and since 2015 he is member of the ENETS Advisory Board.

Ferone, Diego – MD, PhD, Professor / Session 3Diego Ferone is Professor of Endocrinology at the University of Genova, Italy, General Secretary of the Italian Endocrine Society, member of the ENETS Advisory Board. He obtained a degree in Medicine and the postgraduate degree in Endocrinology at the University of Naples and his PhD degree at the Erasmus University, Rotterdam, the Netherlands. He received Italian Endocrine Society awards (best young investigator and best senior scientist) and best researcher award in neuroendocrine tumors field. He is expert of physiopathology and treatment of pituitary and neuroendocrine tumors, physiopathology of GPCRs in the immune

and neuroendocrine systems, medical therapy of pituitary and neuroendocrine tumors. Diego Ferone is author of more than 200 articles and presenter of more than 500 lectures in international and national meetings. He has organized several congresses and workshops for the Italian Endocrine Society and for the ENEA.

Frilling, Andrea – MD, PhD, Professor / Session 8AAndrea Frilling is currently affiliated as Professor of Surgery and Chair in Endocrine Surgery with the Imperial College London, UK. She has received her primary medical education in Germany. After her general surgical training she specialized in endocrine surgery and hepato-pancreato-biliary surgery. She conducted comprehensive clinical research on multimodal treatment of neuroendocrine tumors. She is intensively working towards clinical implementation of novel molecular imaging techniques, targeted treatment options and identification of novel biomarkers. In 2012 she organised an International Consensus Conference on Neuroendocrine Liver Metastases and

developed guidelines including an algorithm for their management. Together with an interdisciplinary group at the Imperial College London she successfully accomplished the ENETS CoE certification program with an emphasis on early diagnosis, multimodal treatment and translational research.

Fröhling, Stefan – MD, Professor / Session 7Stefan Fröhling heads the Section “Molecular and Cellular Oncology” at the National Center for Tumor Diseases Heidelberg, Germany, and co-directs MASTER (Molecularly Aided Stratification for Tumor Eradication Research), a cross-institutional precision oncology program of the German Cancer Consortium. He trained in internal medicine and hematology/medical oncology at Ulm University Hospital, where he was involved in pivotal work identifying genetic abnormalities that define disease subgroups and treatment outcome in acute myeloid leukemia. His postdoctoral work at Brigham and Women’s Hospital, Boston, USA, expanded

these findings by applying functional genomics to identify novel therapeutic targets in hematologic and solid-organ malignancies. In 2012, Stefan moved to Heidelberg, where he works to bring molecular stratification and targeted approaches to patient treatment and clinical trials across tumor types.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

49

Garcia-Carbonero, Rocio – Professor / ENETS Postgraduate CourseRocio Garcia-Carbonero is a medical oncologist with particular expertise in gastrointestinal neoplasias. She is an associate professor and coordinates the Gastrointestinal (GI) Tumor Unit at the Hospital Universitario Doce de Octubre in Madrid. She is a member of the ENETS Executive Committee and of the Spanish Society of Medical Oncology (SEOM). She is deputy-Chair of the ESMO e-learning and Continued Medical Education Working Group (ECMWG) and an active member of various scientific societies (ASCO, ESMO, ENETS, SEOM) and collaborative groups (EROTC, GETNE, TTD). She is a national leader in the field

of neuroendocrine tumors, being the current president of the Spanish cooperative group in NETs (GETNE). She is actively involved in clinical and translational research, and is a member of the Scientific Advisory Group (SAG) for Oncology at the European Medicines Agency (EMA) since 2008. Her major areas of research interest are the development of new drugs or therapeutic strategies in the field of GI tumors, particularly NETs and colorectal cancer, and the development of biomarkers of diagnostic or therapeutic interest in this field. She has published more than 80 papers in peer-reviewed journals, as well as many book chapters.

Geilvoet Wanda – RN, BN, MANP / Nurse WorkshopWanda Geilvoet works at the Erasmus Medical Center, ENETS Center of Excellence, in Rotterdam, the Netherlands. From 2001, she has worked as a clinical endocrinology nurse. Since 2007 she works as a nurse practitioner in the outpatient clinic for patients with endocrine tumors including GEPNET patients. She works as a patient coordinator and contact person for GEPNET patients and their families in the NET-outpatient clinic and the joint clinic for endocrinology and surgery. She is an active member of the tumor board for endocrine tumors and closely involved with the ENETS Center of Excellence audits in her hospital. She is the Secretary of

the ENETS Nurse Group, an active member of the Dutch Endocrine Nurses Group (LWEV).

Glasberg, Simona – MD / Interactive Workshop 3Head of the Neuroendocrine Tumor Unit, Endocrinology & Metabolism Department, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. A specialist in endocrinology and internal medicine, Dr. Glasberg completed a fellowship in Neuroendocrine Tumors and Endocrine Oncology at St. Bartholomew’s Hospital, London, UK. Established as one of the foremost experts in the diagnosis and management of NETs in Israel, Dr. Glasberg is a member of the ENETS Advisory Board. She has published extensively in peer-reviewed journals and presented at national and international conferences on the topic of NETs. She

is the recipient of the prestigious 2017 Israel Endocrine Society Lindner Prize, in recognition for her scientific achievements and contribution in the field of NETs.

Gorbunova, Vera – MD, PhD, Professor / Session 9Professor Vera Gorbunova has been the Chief of the Chemotherapy Department of the Russian Oncological Scientific Center at the Academy of Medical Sciences from 1989 till 2017. Currently she serves as senior scientific advisor at the department of chemotherapy. She has been a Full Professor since 1995. Professor Gorbunova has participated in more than 150 clinical studies as a principle investigator since 1994. Areas of her scientific interest include but are not limited to lung, breast, ovarian, kidney cancer, carcinoma of the uterine and cervix, antiemetic therapy and others. She is currently working on clinical investigations in gastric cancer and the

treatment of chemotherapy-induced anaemia. Professor Gorbunova has published more than 554 scientific peer-reviewed articles to date. Dr. Gorbunova has organized and is the President of Russian Neuroendocrine Tumors (NET’s) Society.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

50

Grande, Enrique – MD, PhD, Msc / Session 3Dr. Grande has been recently appointed as Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Madrid International Cancer Center. Dr. Grande was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a masters degree in the molecular biology of cancer. He is author of more than 150 manuscripts in peer-reviewed journals, Dr. Grande is also founder of the Spanish group for research on orphan and uncommon tumors (GETHI) and an active member of the Spanish Task Force Group for NETs (GETNE). Dr. Grande is

Professor at the Francisco de Vitoria University, Madrid, Spain, and had active participation at the most recent trials in the field of NETs.

Gross, David – MD, Professor / ENETS Postgraduate Course, Session 4ADavid Gross is Associate Professor (emeritus) at the Hebrew University-Hadassah Medical School and former head of the Neuroendocrine Tumor Unit at the Hadassah-Hebrew University Medical Center. He is a graduate (MD) of the Hebrew-University-Hadassah Medical School and subsequently specialized in internal medicine and endocrinology. He was appointed senior physician in the Endocrine service at Hadassah-Hebrew University Medical Center, were he developed an interest in patients afflicted by endocrine malignancies. Subsequently he was appointed head of the newly established Neuroendocrine Tumor Unit. His scientific interests include

all aspects of clinical management of patients with endocrine tumors. At the basic level - the role of autophagy in the survival of neuroendocrine tumor cells and the mechanism of expression of somatostatin receptors.

Grossman, Ashley – BA, BSc, MD, FRCP, FMedSci, Professor / ENETS Postgraduate Course, Session 4AAshley Grossman completed his first degree in Psychology and Social Anthropology at the University of London, and then entered University College London where he received degrees in Anatomy and Medicine. He is Professor of Endocrinology and Fellow of Green-Templeton College at the University of Oxford, Professor of Neuroendocrinology at Barts and the London School of Medicine, and Consultant NET Endocrinologist at the Royal Free London. He was awarded the ESE Geoffrey Harris Prize in 2014, and the Iain MacIntyre Prize in 2017. He has been President of

the ENEA, the Society for Endocrinology (2012-2014), Chairman of UKI NETS (2010-2012), and was President of the Pituitary Society (2015-2016). He has published more than 850 papers in journals and book chapters.

Hollander, Ron / ENETS/INCA SymposiumRon Hollander has been working in the non-profit healthcare and human services arena for over four decades. He currently serves as the Immediate Past President of the International Neuroendocrine Cancer Alliance (INCA). INCA is dedicated to serving as the global voice for NET patients and committed to working with all stakeholders to ensure that patients around the world have access to the latest treatments, best research and ultimately a cure. Ron Hollander previously served as the Executive Director of the Neuroendocrine Tumor Research Foundation, leading the foundation’s efforts to raise funds to advance NET research, identifying

and financing potentially breakthrough research around the world, and supporting patients and families through information and education programs.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

51

Jensen, Robert – MD / Session 6Dr. Robert T. Jensen is Chief of the Cell Biology Section, Digestive Diseases Branch, Diabetes, Digestive and Kidney Diseases of the National Institutes of Health, USA. He has had a long-standing interest in pancreatic endocrine tumor syndromes, particularly using the Zollinger-Ellison syndrome as a model in which sufficient numbers of patients could be obtained to allow systematic studies. His studies have involved natural history, diagnosis, systematic analysis of imaging studies, medical control of the gastric acid hypersecretion, role of surgery, molecular-pathologic-clinical correlations to identify prognostic factors and treatment of patients with

advanced disease. In addition, he also performed basic science studies related to the cellular basis of action of gastrointestinal hormones including studies of cell signaling, pharmacology and molecular pharmacology. He has published more than 550 papers and more than 90 chapters.

Kaltsas, Gregory – MD, FRCP (Lon), Professor / ENETS Postgraduate Course, Session 3Professor Kaltsas was trained in General Medicine-Endocrinology in London, United Kingdom, where he developed a special interest in neuroendocrinology and endocrine oncology and particularly in neuroendocrine neoplasms. He is currently a Professor of General Medicine-Endocrinology at the National and Kapodistrian University of Athens and the Head of the ENETS Center of Excellence for Neuroendocrine Tumors in Athens, Greece. He is also interested in adrenal physiology and adrenal neoplasms. He is a member of the Executive Committee

of ENEA and of the ENETS Advisory Board and acts as an Associate Editor in three international scientific journals. He has published several peer review articles in the field of neuroendocrine neoplams and acts as a reviewer in numerous scientific journals.

Kianmanesh, Reza – MD, PhD, Professor / Session 5BReza Kianmanesh is full professor in digestive and oncological surgery (Paris 7 University), he is, since 2011, Head of the Department of General, Digestive and Endocrine Surgery, R. Debré University Hospital, Reims, France. In addition to serving as member of the ENETS Executive Committee, he has been active within the ENETS Advisory Board. He specializes in HPB surgery, LT, peritoneal carcinomatosis, cytoreductive surgery and multidisciplinary treatment of digestive NETs, which represent his preference domains of competence. He collaborates actively with Prof. G. Cadiot, Reims Hospital-University and inside the French NET regional and national

and international networks (RENATEN, GTE). He studied medicine in Paris, France. He got his PhD in cancer gene therapy in NY, USA, and became Assistant-Professor in HBP Surgery and Liver Transplantation Division, Beaujon Hospital, Clichy, France. He became member of ENETS Advisory Board in 2007.

Kim, Michelle Kang – MD, PhD, AGAF, FASGE / Session 2Dr. Kim is Director of the Center for Carcinoid and Neuroendocrine Tumors at Mount Sinai Hospital, New York, NY, USA. She is also Associate Professor of Medicine at Mount Sinai School of Medicine and Associate Director of Endoscopy. Dr. Kim received undergraduate and medical degrees from Harvard College and Stanford University School of Medicine. She pursued postgraduate training at New York Presbyterian Hospital (Cornell). Dr. Kim’s clinical and research interests are in translational and epidemiologic approaches assessments of outcomes in patients with gastrointestinal neuroendocrine tumors. She has published nearly

50 publications in high impact journals such as Journal of Clinical Oncology and Gastroenterology and has lectured nationally and internationally on carcinoid and neuroendocrine tumors.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

52

Knigge, Ulrich – MD, DMSc, Professor / ENETS Postgraduate Course, Interactive Workshop 2Ulrich Knigge is Associate Professor of Gastrointestinal Surgery at Rigshospitalet, University of Copenhagen, Denmark. He became MD 1978, DMSc 1989, Specialist in Surgery 1991 and Specialist in Gastrointestinal Surgery 1994. Since 1994 he has been Director of the Neuroendocrine Tumor Centre of Excellence at Rigshospitalet with around 400 new referrals yearly. In 2009, under his guidance, the NET Centre at Rigshospitalet was certified as ENETS Centre of Excellence (CoE) among the first six CoE in Europe. He was member of the Board of the Danish Endocrine

Society 1992-1996, co-founder and vice-chairman of the Nordic Neuroendocrine Tumor Society. He has since 2008 been member of the ENETS Advisory Board. He has organized several national and international symposia on neuroendocrine neoplasms. He has published around 200 original papers, reviews and book chapters in peer-reviewed predominantly international journals.

Kolarova, Teodora / ENETS/INCA SymposiumTeodora Kolarova serves as Executive Director of the International Neuroendocrine Cancer Alliance, which is an umbrella group of 20 organizations from 17 countries - the global voice in support of neuroendocrine cancer patients. She has been a member of INCA’s Board of Directors and Chairperson of INCA’s Communications Committee 2012 – 2015 and has served as INCA President 2014 - 2015. The key priority in her advocacy work is the development and enforcement of a sustainable collaborative model to approach cancer care with patients in the focus. Fostering meaningful relationships that last, she has helped INCA get recognized as a key

partner in many international initiatives. She became the first patient representative on the ENETS Advisory Board.

Kos-Kudła, Beata – MD, PhD, Professor / Session 10Professor Beata Kos-Kudła currently serves as Chair of the Department of Endocrinology and Neuroendocrine Tumors at the Medical University of Silesia, Katowice, Poland. She founded Polish Network for Neuroendocrine Tumors and National NET Register. She is President Elect of the Polish Society of Endocrinology, a member of Executive Committee of the European Society of Endocrinology and a member of the ENETS Advisory Board, where she has also served as a member of the Executive Committee, and was an active participant in creating the European NET Register. She has published over 500 publications. Being active participant in

the work of many scientific societies and organizer of numerous, scientific congresses, she is also Editor in Chief of Polish Journal of Endocrinology.

Lawrence, Ben – MD, MBChB MSc FRACP / ENETS/INCA SymposiumDr. Lawrence is a Medical Oncologist at Auckland City Hospital, and Senior Research Fellow at the University of Auckland, Australia. He co-leads a clinical and translational research team focused on improving the care of people with NETs. The program includes a national NET tumor board, a nationwide registry of people with NETs, and a genomic research group. He has a close relationship with Unicorn NZ, the patient advocacy group for people with NETs in New Zealand.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

53

Lepage, Côme – MD, PhD, Professor / Session 2Since 2009, he has been Professor of hepato-gastroenterology and digestive oncology at the University of Burgundy. Since 2012, he has been the Head of the INSERM Unit Epidemiology and Clinical Research in Digestive Oncology (EPICAD). His main interests include trends and inequalities in cancer incidence, mortality and survival, and the application of these metrics to public health policy and cancer control. As a physician he is also involved in clinical research in particular in NET cancers.

Leyden, Simone / ENETS/INCA SymposiumSimone Leyden, co-founded the Unicorn Foundation in 2009. After finishing her Bachelor of Business Management/Marketing Degree from Monash University, Simone went into the field of Advertising/ Marketing and has held various positions. After 12 years in Advertising and various senior positions, Simone took on the full time role of Chief Executive Officer of The Unicorn Foundation in April 2011. In her role as CEO Simone advocates for greater access to treatments and diagnostics, raises funds for the NET Nurse Support Service and research, and raises awareness about NET cancers within the medical community and general public. Simone is

an active member of many associations including standing committee member of Australia’s National Patient and Carer Organisation Committee, President and Communications lead of the International Neuroendocrine Cancer Alliance (INCA), and participant in many Health Technology Assessment (HTA) committees including HTAi patient panel. Simone is passionate about improving the lives and outcomes of NET Cancer patients around the world and bringing the patient voice to the forefront of research.

Mailman, Josh / ENETS/INCA SymposiumJosh Mailman is a passionate, internationally-recognized advocate for NET patients, treatment and research. He is President of the NorCal CariciNET Community, one of the largest NET patient communities in the US. A patient advisor sought after by organizations developing guidelines, reviewing research, and conducting educational programs for neuroendocrine tumors. His roles include serving on the National Cancer Institute’s GI Steering Committee and Task Force on Neuroendocrine Tumors, Board and Research Committee, Neuroendocrine Tumor Research Foundation and Patient Advocacy Advisory Board of the SNMMI (Inaugural Chair).

In 2015, he was honored with two major awards: The Warner Advocacy Award, which recognizes leadership and advocacy for NET patients, and the SNMMI’s President’s Award for his work in nuclear medicine.

Merola, Elettra – MD, PhD / Interactive Workshop 1, Grant Winner Presentations Dr. Elettra Merola is a gastroenterologist and researcher currently working at the Friedrich-Alexander University Erlangen, Germany. She received her medical degree in 2005 from Campus Bio Medico, Rome, Italy. She completed her residency in Gastroenterology in 2009 and her PhD in Digestive Oncology in 2013 at Sapienza University, Rome, Italy, where she worked until May 2017. In March 2017 she was awarded with the ENETS CoE Excellence Academy Fellowship and is a member of the ENETS young researcher group EEAF. She has been a visiting researcher in different institutes (Charité University, Germany, University of Illinois,

Chicago, Temple University, Philadelphia, USA). She has led several cooperative studies aimed to improve clinical management of patients affected by neuroendocrine tumors.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

54

Meyer, Tim – MD, PhD, Professor / Session 9Tim Meyer is Professor of Experimental Cancer Medicine at UCL and Consultant in Medical Oncology at the Royal Free and ULCH Hospitals, London, UK. He is Director of the UCL Experimental Cancer Medicine Centre and Cancer Lead for the NIHR UCLH/UCL Cancer Clinical Research Facility. He is a member of the multidisciplinary Neuroendocrine Unit at the Royal Free Hospital, London and Chair of the NCRI NET Clinical Studies Group. His main interests are in cancer drug development and the application of circulating tumor cells (CTCs) as a biomarker in NET.

Modlin, Irvin – MD, PhD, Professor / Session 10Professor Irvin Modlin was Vice Chair of Surgery at Yale and director of the neuroendocrine pathobiology group for 35 years. He has authored ~ 500 publications and 16 books, including the biology of acid peptic disease, neuroendocrine tumors, laparoscopic surgery, histories of the philosophy of science and medicine, the evolution of medicine in cities and Dutch art. His scientific interests include proton pump regulation in parietal cells, ECL and EC cell purification and molecular pathobiology. Current investigations focus on multianalyte circulating transcriptomic analysis and mathematical algorhythmic modelling in the prediction of disease status

and therapeutic efficacy. His present work addresses the philosophical application of Borgian fabulism to scientific realism in the assessment of the comparable ontology of unobservable entities.

Munk Plum, Lise – Advanced Nurse Specialist, RN, MCN / ENETS/INCA Symposium, Nurse SessionLise Munk Plum is employed at University Hospital Copenhagen, Denmark, at Rigshospitalet Neuroendocrine Tumor Center of Excellence (CoE) in Medical Endocrinology and Surgical Gastroenterology Unit. She is trained and educated in cancer nursing and has been working with neuroendocrine tumor patients for more than 20 years. She is member of ENETS NET nurse group and a board member of the Danish patient advocacy group Netpa.

Nicolas, Guillaume – MD / Session 3Dr. Guillaume Nicolas is a Consultant in Nuclear Medicine at the University of Basel Hospital, Switzerland. He completed his medical studies at J. Fourier University in Grenoble, France, before receiving his MD Degree from the University of Basel. He received the Helmut Hartweg Scholarship in 2014 and completed a Clinical Research Fellowship at the Neuroendocrine Tumour Unit of Prof. Martyn Caplin, Royal Free Hospital, London, UK. Dr. Nicolas has authored numerous publications and is quickly building a reputation in the field of molecular imaging and PRRT of NETs. His research on radiolabelled somatostatin receptor antagonist has been recognised with a number

of awards, including the Best Oral Presentation at the ENETS Annual Conference 2016.

Niederle, Bruno – MD, Professor / Session 5BDr. Niederle is Professor of Surgery, current Chief of the Department of Surgery, Franziskus Spital, Vienna, Austria, and was former Chief of the section “Endocrine Surgery”, Medical University of Vienna. After studying at the Medical University of Vienna he completed his surgical training in 1989 and was then Senior Resident in the Department of Surgery till 2016. In 2001 he became Professor of Endocrine Surgery. He is a Fellow of the European Board of Surgery (FEBS – Endocrine Surgery), Fellow of the Royal College of Surgeons [FRCS-England] and Fellow of the American College of Surgeons [FACS]. He was founding member and president

(2012-2014) of the European Society of Endocrine Surgeons. He is member of the ENETS Advisory Board and has published over 300 articles in international, peer reviewed journals.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

55

Öberg, Kjell – MD, PhD, Professor / Session 10Senior Professor at Dept. of Medical Sciences at Uppsala University, former Head of the Department of Endocrine Oncology, University Hospital Uppsala, Sweden. Prof. Öberg founded the Dept. of Endocrine Oncology at Uppsala University Hospital and has 40 years of experience in the field of neuroendocrine tumors. He is one of the founders of ENETS and held the position of ENETS Chairman from 2012-2014. He also headed the first ENETS Summer School, which took place in Uppsala, Sweden in 2014. Dr. Öberg is a member of the Royal Society of Sciences, Honorary Member of the Finnish Oncology Society, Finnish Endocrine Society and

Spanish Neuroendocrine NET-work. Furthermore, he is a member of several other national and international research and scientific boards and many scientific journal review boards. He was the chairperson for the Centre of Excellence Endocrine Tumors, Uppsala University Hospital until May 2013.

O’Toole, Dermot – Professor / ENETS Postgraduate Course, ENETS/INCA SymposiumDermot O’Toole is Professor in Gastroenterology and Clinical Medicine at Trinity College Dublin, University of Dublin, Ireland, and is Consultant Gastroenterologist and the Neuroendocrine Tumour specialist in the ENETS Centre of Excellence in St Vincent’s University Hospitals Dublin. He graduated from Trinity College Dublin and has postgraduate degrees from Trinity College Dublin, University of Paris and University of Angers. His major research interest is in gastrointestinal cancer biology especially focusing in neuroendocrine-related diseases and early

neoplasia in the gastrointestinal tract (Barrett’s oesophagus, gastric and colorectal cancers). He leads the national endoscopic interventional program for early digestive cancers and is also national clinical lead for the neuroendocrine tumour group. He also serves on the ENETS Executive Committee and has helped develop many guidelines papers and standards of care initiatives in the field of NET as well as chairing the ENETS-driven European Centre of Excellence program. He has been principal investigator and/or coordinator in many national and international research activities in GI oncology. He is a member of several professional bodies in Europe and North America and has served as advisor on several national health care projects/initiatives and on patient advocacy groups.

Papotti, Mauro Giulio – Professor / Session 8APresent position: Full Professor of Pathology, University of Turin, Italy; Head of Pathology at Città della Salute Hospital in Turin. Education: Medical Doctor degree cum laude at the University of Turin in 1980. Postgraduate resident programs in: Oncology (1983) and Pathology (1991). Teaching activity: Pathology courses for medical students, laboratory technicians and residents Diagnostic activity: cytopathology, pulmonary pathology, endocrine pathology. Main research interests: Application of immune- and molecular markers to human tumors for diagnostic, prognostic and predictive purposes. Pathological characterization of endocrine and

thoracic tumors. Publications: over 400 peer-reviewed papers and 400 meeting abstracts. Editorial boards: Virchows Arch, J Pathology, Am J Clin Pathol, Arch Pathology, Endocrine Pathol, J Clin Pathol.

Partelli, Stefano – MD, PhD / Session 5B Dr. Stefano Partelli serves as consultant surgeon and Assistant Professor at Pancreatic Surgery Unit of “Vita-Salute” University, San Raffaele Hospital in Milan, Italy. After the degree in medicine and the general surgery board certification at the University of Verona, he received the PhD degree in hepatobiliary and pancreatic surgical science. He has authored over 100 publications in peer-reviewed journals with a special interest in pancreatic neuroendocrine neoplasms. He was awarded with best oral communication (2nd place) by ENETS in 2011 and 2012. He is an active member of ENETS since 2011 as well as member of the scientific committee

of the Italian Association for Neuroendocrine Tumors (It.a.net).

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

56

Pascher, Andreas – MD, PhD, MBA (HCM), FEBS, Professor / Session 5B Andreas Pascher is Professor of Surgery at the Charité – Universitaetsmedizin, Berlin, Germany. He currently serves as Deputy Chair of the Department of Surgery and Director of HBP, Neuroendocrine Tumor - as well as Transplant Surgery. He is specialized and board-certified in gastrointestinal, hepatobiliary, as well as transplant and robotic surgery. He has been a Fellow of the European Board of Surgeons in transplant surgery since 2010 (UEMS). In 2010 he also completed his master in health care management at the Berlin School of Economics and Law. Andreas Pascher published over 230 peer-reviewed publications and various book articles.

Pavel, Marianne – MD, Professor / Session 8AMarianne Pavel is a Senior Physician and Chair of Endocrinology at the University of Erlangen, Germany. Her major focus in medicine is neuroendocrine tumors for more than 20 years. She is first author of the ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary (2012/update 2016). Board certified as a specialist in internal medicine in 2000 and endocrinology/diabetes in 2001, she was appointed as Vice Head of the Division of Endocrinology and Metabolism at the Friedrich-Alexander University Erlangen in 2001. She took a position

as an Assistant Director at the Charité University Hospital, Berlin in 2007 and was conferred a Professorship for NET Disease at the Charité University in 2010. She has conducted numerous clinical trials in the field of NET. In 2009, under her guidance, the NET Center at the Charité University was certified as the first ENETS Center of Excellence. Since April 2014 she is a member of the ENETS Executive Committee.

Peeters, Marc – MD, PhD / Professor / Session 6Marc Peeters is Professor of Oncology at the Antwerp University, Belgium. He is Head of the Oncology Department at the Antwerp University Hospital and Coordinator of the Multidisciplinary Oncology Center Antwerp. He is also Chairman of the College of Oncology. Previously, he was Coordinator of the Digestive Oncology Unit at the University Hospital in Ghent, Belgium. He is Secretary of the Flemish Society of Gastroenterology. He is Vice-President of the Belgian Group of Digestive Oncology and member of different international Oncological organisations such as ESMO, ASCO. His research interests have included the identification of molecular markers

and therapy modulation in digestive tumors. He has been involved in many clinical studies on therapeutic agents for gastrointestinal tumors. He published numerous articles in peer reviewed journals and was author of several chapters in oncology books.

Pipinikas, Christodoulos – MD, PhD, BSc, MSc / Grant Winner Presentations Having completed a BSc in Molecular Biology and MSc in Human Molecular Genetics (Imperial College University of London, UK) Christodoulus Pipinikas started his PhD in Cancer Genetics in 2003 with the aim of developing a new, more accurate, non-invasive test for the early prostate cancer diagnosis leading eventually to a patent generation. In 2009, he joined UCL where he worked towards understanding the epigenetic changes associated with the progression of pre-invasive lung squamous cell carcinoma into cancer. In 2014, he joined Dr. Thirlwell’s group (UCL Cancer Institute) to work on neuroendocrine tumors. Using DNA methylation, exome and

RNA sequencing, he is working towards understanding the genetic/epigenetic mechanisms associated with lung NET development/progression aiming to identify classification/sub-grouping biomarkers and novel targets for developing new therapies. In 2016, he was awarded a NET Patient Foundation award and in 2017 a ENETS CoE Excellence Academy Fellowship grant.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

57

Pitfield, Deborah – RGN / Nurse WorkshopDeborah Pitfields’ nursing background is medical oncology and she has over 25 years of experience. Her career began in 1985, when she qualified at the Royal London Hospital, London, UK, and since then, she has been fortunate to have varied experience including an Oncology Research Sister, a Cancer Information Officer at BACUP, a Chemotherapy Nurse, and then as Team Lead in Oncology Clinical Trials in Cambridge. Her current role is as NET Specialist Nurse at Addenbrooke’s Hospital, Cambridge, UK; this center is currently in the process of applying for ENETS Centre of Excellence. Her chief responsibilities include: caring

for NET patients and those patients with hereditary endocrine neoplasia syndromes such as MEN1, SDHB gene carriers. She is also involved in the care of NET patients receiving treatment with targeted agents such as sunitinib, PRRT and systemic chemotherapy. Finally, she has recently joined the ENETS Nurses Committee and she is looking forward to working with them.

Prasad, Vikas – MD, PhD, Associate Professor / Interactive Workshop 1Prof. Prasad is a nuclear medicine physician with 13 years of experience in the field of neuroendocrine tumor. Before joining Charité Universitätsmedizin, Berlin in 02/2011 he worked with Prof. Richard P. Baum at the Zentralklinik Bad Berka, Germany. In 1/2018 he joined the Uniklinik Ulm, Germany, as Deputy Director, Department of Nuclear Medicine. He is also Visiting Assoc. Prof. Division of Nuclear Medicine, Univ. of Cape Town, SA. He has written more than 75 peer reviewed articles, 8 book chapter and more than 100 abstracts. He has given more than 50 invited lectures and has organised symposia and workshops primarily

on ‘Theranostic’ applications of radionuclides. His primary research interests are in PET/CT, PET/MRI, new radiotracers, combination of in-vitro and in-vivo molecular imaging, development of new image processing softwares and implementation of surrogate markers and genetic information in ‘theranostics’.

Raymond, Eric – MD, PhD, Professor / Session 7Eric Raymond is board certified MD specialized in medical oncology and obtained a PhD degree in cellular and molecular biology, working on preclinical mechanisms of action and combinations of several novel anticancer drugs. He has been appointed as full professor of oncology at Paris VII University and Chair of the Medical Oncology Department at Bichat-Beaujon University Hospitals, Paris, France, in 2004. He was also appointed as full professor of medical oncology at the University of Lausanne in 2014. Prof. Raymond joined the Paris Saint-Joseph Hospital Group in 2016 as a Chair of Medical Oncology. He is an active member

of several international groups such as EORTC, ENETS, ASCO, AACR and is participating to several boards for non-for-profit organisations and industry.

Rindi, Guido – MD, PhD, Professor / Session 1MD in 1982 and specialist in Human Pathology in 1986 at the University of Pavia, Italy, obtained his PhD in 1991 at the University of London, UK, and then spent two years as Fogarty Fellow at Tufts University – New England Medical Center, Boston, USA. Chair of Pathology in 2001 at the University of Parma, in 2009 moved to the Università Cattolica – Policlinico A. Gemelli in Rome as Head of the Institute of Pathology and Chief of the Histopathology Service. Co-founder of the European Neuroendocrine Tumor Society (ENETS), his research focuses on neuroendocrine cells and neuroendocrine pathology embracing mouse tumor modelling, human

cancer genetics and relevant clinical-pathological aspects including grading and staging.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

58

Rinke, Anja – MD / Session 5AAnja Rinke is currently Center Coordinator at the ENETS Center of Excellence at the University Hospital Marburg, Germany. She studied medicine at the Philipps University Marburg between 1988 and 1995 and started her residency at the University Hospital Marburg in the Department for Gastroenterology in 1995. After her board certification for internal medicine in 2003 she specialized in gastrointestinal cancers, particularly neuroendocrine tumors. She is a member of the ENETS Advisory Board, of the Advisory Board of the German NET Registry, member of the German Internists (BDI), German Society for Digestive and Metabolic Diseaes

(DGVS) and the German working group of internists in Oncology (AIO).

Rubin, Mark Andrew – MD, Professor / Session 1 Prof. Mark Rubin is a leader in the fields of prostate cancer biology and precision medicine as it applies to all cancers. Rubin’s laboratory led a series of landmark studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive different types of this cancer. Prof. Rubin has translated many of his genomic discoveries into clinical tests that are currently patented and standardly used in the diagnosis and treatment of prostate cancer. In May 2017, Prof. Rubin joined the University of Bern, Switzerland, as Professor and Director of the Department for Biomedical Research and also as Project Leader for Precision

Medicine at the University Hospital of Bern.

Ruszniewski, Philippe – MD, Professor / Interactive Workshop 2Professor Philippe Ruszniewski works currently in the Department of Gastroenterology-Pancreatology at Beaujon Hospital, Clichy, France. He is Professor of Gastroenterology at Paris Diderot Medicine Faculty and Dean of the Faculty since July 2015. His main areas of interest are neuroendocrine tumors and pancreatic diseases. He served as President of the European Neuroendocrine Tumor Society (ENETS) between 2010 and 2012, then Vice-Chairman, and he is currently a member of the ENETS Advisory Board. He has published 410 papers in international journals and serves as a reviewer for leading journals in

gastroenterology and digestive oncology. He is Past President of the French Society of Gastroenterology, and a member of numerous societies in the field of gastroenterology, pancreatology and digestive oncology.

Salazar, Ramon – MD, PhD / Session 4BRamon Salazar is Head of Medical Oncology Department at Catalan Institute of Oncology (ICO), Spain. He leads Early Clinical Research, Colorectal and Neuroendocrine Tumor Units at ICO L’Hospitalet, Barcelona. Dr. Salazar completed his MD and PhD at Hospital Santa Creu i Sant Pau in Barcelona, undertook a research fellowship at Beatson Oncology Centre in Glasgow, Scotland (ESMO clinical fellowship grant) and underwent further training at Neuroendocrine Oncology Unit, University of Uppsala, Sweden. He has been member of ESMO and is board member of the Spanish Cooperative Group for Gastrointestinal Tumour

Therapy, and also serves as member of ENETS Advisory Board. He has published approximately 150 peer-reviewed articles, written numerous book chapters and monographs, and organised multiple symposia and teaching activities.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

59

Scarpa, Aldo – MD, PhD, Professor / Session 1Prof. Scarpa is Chair of the Department of Pathology at Verona University and Director of the ARC-Net Centre for applied research on cancer at Verona University, Italy. He is leader of the Italian effort in the International Cancer Genome Consortium funded by the Italian Ministry of Research and Ministry of Health, Coordinator of the Italian National Consortium for innovative molecular diagnostics in pancreas cancer funded by the Associazione Italiana per la Ricerca sul Cancro (AIRC). The research focus of Prof. Scarpa is the translation into clinical practice of molecular subclassifications of cancers with prognostic-therapeutic relevance. He has

published over 400 peer-reviewed papers. His interest in neuroendocrine neoplasms dates back to 1992 and ranges from histopathology and staging/grading to molecular characterization.

Scoazec, Jean-Yves – MD, PhD, Professor / ENETS Postgraduate Course, Session 4BJean-Yves Scoazec is Professor of Pathology at Université Paris XI and Head of the Department of Biopathology, Gustave Roussy Cancer Campus, Villejuif, France. Since 2015, he is director of AMMICa (Molecular Analysis, Modelling and Imaging of Cancer), INSERM US23/CNRS UMS3655, Villejuif. His personal research interests are mainly focused on digestive neuroendocrine tumors and, especially, on their mechanisms of tumorigenesis and progression. Professor Scoazec has published more than 400 original articles. He is a member of the

board of the Groupe d’Etude des Tumeurs endocrines (GTE) and of the ENETS Advisory Board. He is the coordinator of the French national expert network for the pathological diagnosis of neuroendocrine tumors of the adult, supported by the French Cancer Institute.

Singh, Simron – MD, MPH / Session 8A Dr. Singh is the Co-Head of the Susan Leslie Clinic for Neuroendocrine Cancers at the Odette Cancer Center in Toronto, Ontario – the largest of its kind in Canada. He specializes in improving clinical outcomes as well as quality improvement in the care of patients with neuroendocrine cancers. He is the Co-Chair of the Commonwealth Neuroendocrine Tumour research collaboration as well as the North American Neuroendocrine Tumor Society Annual Meeting Co-Chair. He has published extensively on NETs and holds numerous peer-reviewed grants to improve the care of patients with NETs. He has been invited extensively around the

world to speak on improving disease outcomes in NETs. Dr. Singh is an associate scientist at the Institute for Clinical Evaluative Sciences in Toronto, Canada as well as the Provincial Head of the Person Centered Care portfolio at Cancer Care Ontario.

Sorbye, Halfdan – MD, PhD, Professor / ENETS Postgraduate Course, Session 5AProfessor and Head of NET and GI section at Haukeland University Hospital, Bergen, Norway. Member of the ENETS Advisory Board since 2013, ESMO (European Society of Medical Oncology), Faculty Member for Endocrine Tumors and for the Gastro-Intestinal Tumors. 100 peer review publications, 3330 citations. Major research focus on neuroendocrine neoplasms WHO G3: gastroenteropancreatic neuroendocrine carcinoma (NEC) and tumors (NET G3). Most relevant publications: Nordic NEC (Ann Oncol 2013), High-grade GEP-NEC (UpToDate), GEP HG NEC (Cancer 2014).

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

60

Thirlwell, Christina – MD, PhD, Associate Professor / Session 7Dr. Thirlwell is a Senior Lecturer and Consultant in Medical Oncology at the Royal Free Hospital NET Unit (since 2010) and University College London Cancer Institute, London, UK. She is Chair of the UKINETS Research Committee, Scientific Board member of the NET Research Foundation and undergraduate academic lead at UCL Cancer Institute. She completed a PhD in colorectal cancer genetics funded by the Medical Research Council. Dr. Thirlwell leads a research group at the UCL Cancer Institute and has a particular interest in integrated genomic and circulating free DNA analysis of neuroendocrine tumors with the aim of identifying

novel therapeutic targets and personalizing therapy. To-date she has successfully identified sub-groups of NETs with poorer clinical outcomes, and has successfully isolated and sequenced DNA from circulating NET cells in the bloodstream (CTCs). She has delivered plenary lectures at numerous national and international meetings, and received national and international prizes and awards for research undertaken by her team.

Tiensuu Janson, Eva – MD, Professor / Session 6Eva Tiensuu Janson is a Professor of Medicine and Senior Consultant in Endocrine Oncology at Uppsala University Hospital, Sweden. She serves as the Dean of the Medical Faculty at Uppsala University. She is also the chair of the Nordic Neuroendocrine Tumor Group, a member of ENETS Advisory Board (since 2015) and of ENETS Executive Committee (since 2016). She is active in the Swedish group for endocrine abdominal tumors and has participated in the development of a national caring program for abdominal neuroendocrine tumors (NETs) and a national quality registry for NETs. She obtained Ph.D. in 1995 on

SI-NETs and has published about 120 papers on neuroendocrine tumors. Her research interest is tumor biology and genetics behind development of neuroendocrine tumors, with a focus on hereditary SI-NETs and on the highly malignant G3 neuroendocrine neoplasms. She has participated in many clinical trials and has organized numerous scientific meetings and educational activities in the NET area with a special focus on young scientists and clinicians.

Toumpanakis, Christos – MD, PhD, FRCP / ENETS Postgraduate Course, Session 8ADr. Christos Toumpanakis is a Consultant in Gastroenterology & Neuroendocrine Tumours in the Neuroendocrine Tumour Unit – ENETS CoE, Royal Free Hospital, London, UK, since 2007. He is also an Honorary Senior Lecturer at University College of London, and has been awarded as “Top-Teacher of the Year” in 2007, 2009, 2013 - 2016. He graduated at the University of Athens, Greece (1994), obtained his specialization in Gastroenterology & Hepatology (2004), and his PhD from University of Athens (2007). He has been involved in the area of NETs since

2000. He has presented in several international conferences and published many original papers and reviews. He is a member of the ENETS Advisory Board, member of Executive Committee of UKINETs, co-Editor of ENETS CME program, co-Author of ENETS and UKINET Guidelines, as well as a member of the Advisory Board of “UK NET patients’ foundation”. He is leading a NET Clinical Research Group and his main research interests include NET novel biomarkers & molecular imaging, and carcinoid heart disease.

Valle, Juan – MB, ChB, FRCP, Professor / Session 8A Juan Valle, Medical Oncology Professor at the University of Manchester/The Christie, Manchester, UK, specializes in hepatopancreatobiliary cancers and NETs. He leads The Christie ENETS Centre of Excellence and is a member of the following subgroups of the UK National Cancer Research Institute Upper GI Clinical Studies Group: hepatobiliary, pancreatic and neuroendocrine (which he chaired between 2013-2017). He is Secretary of UKINETS, Co-Chair of the EORTC Hepatobiliary/NET Task Force, the NCI Hepatobiliary Task Force [USA], and Vice-Chair of the Cholangiocarcinoma Foundation Medical Advisory Board [USA]. He is a member of

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

61

ASCO, ESMO, UKINETS and ENETS. He has been awarded a number of research grants leading to numerous publications/presentations at national/international meetings and peer-reviews for many international medical journals.

Van Genechten, Dirk / ENETS/INCA SymposiumDirk Van Genechten is Vice President of the Belgian NET & MEN Association, board member of INCA and is a patient living for over seven years with NET. The Belgian NET & MEN Association is a non-profit organization managed by volunteers, all either patients themselves or directly related to one. He joined the Belgian organization at the start up. He finds great support and comfort in the patient group and decided to help the organization. Dirk Van Genechten has been the Vice President of the Association for nearly four years and represents Belgium in the INCA. He works fulltime as a Managing Director of a European-wide operating

breakdown support company for commercial vehicles.

Volante, Marco – MD, PhD, Professor / Session 6Associate Professor in Pathology, University of Turin, Italy, Director of the Pathology Unit at “San Luigi Hospital”, Orbassano, Turin, Italy. PhD program in Human Oncology, University of Turin, 1997 – 1998, research fellow at the University of Zurich, Switzerland, July – December 1999. >100 lectures at national and international meetings and courses. Editorial Board member of “Pathology Research International”, “Analytical and Quantitative Cytopathology and Histopathology” and “Endocrine Pathology”. >200 publications (Hc index: 43), 11 book chapters. Contributor of the WHO classification of Tumors of Endocrine Organs (years

2004 and 2017); „International award for publishing excellence in the Journal of Clinical Endocrinology and Metabolisms“ (for the paper JCEM 96:2146-2153, 2011). From March 2016, President of the Endocrine Pathology Society, an USCAP affiliate.

Wakelin, Kate – BS (Nursing), Grad. Dip. (Psycho-Oncology) / ENETS/INCA SymposiumKate Wakelin is a Registered Nurse with a Graduate Diploma in Psycho-Oncology. She has been caring for people affected by cancer for over 25 years, in areas including palliative care, radiotherapy, chemotherapy, research and supportive care. Throughout her career, she has maintained a passion for creating and maintaining innovative programs that strengthen the delivery of supportive care to people affected by cancer. She joined the Unicorn Foundation team in 2015 as the NET Patient Support Nurse, providing information and support and facilitating

advocacy for people affected by neuroendocrine tumors throughout Australia, and engaging and linking health professionals with an interest in NETs.

Welin, Staffan – MD, PhD / Session 2 Staffan Welin is the Head of ENETS CoE in Uppsala, Sweden, since 2011. He has worked with NENs for more than 20 years. He has >20 scientific original papers in NENs. He has been the PI in several studies i.e TELESTAR, TELECAST, COOPERATE-2 and subinvestigator in >15 studies. He is a member of the ENETS Advisory Board and Treasurer in the Nordic Neuroentocrine Tumor Group (NNTG).

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

62

Whyand, Tara – B.Sc, M.Sc / Nurse SessionTara Whyand is a dietitian and has specialised in NETs for the past 6 years. She works part-time at the Royal Free Hospital, London, UK, as The Research and Development Dietitian, where she runs research studies, and develops resources such as booklets. She has recently formed the first group of its kind ‚Dietitians Interested in NETs Group (DING)’, to help increase standards within the profession. She publishes her data at conferences and presents nationally and internationally. She sees patients from around the world in her private practice and she works closely with the NET Patient Foundation and PLANETs.

Wiedenmann, Bertram – MD, PhD, Professor / Life Achievement Award 2018, Session 7, Nurse Session Bertram Wiedenmann is Professor of Internal Medicine and Gastroenterology, since 1997 Head of the Department of Gastroenterology and Hepatology, Charité University Hospital, Berlin, Germany, and since 2017 a Member of the Charité Supervisory Board. Following his discovery of synaptophysin (1985), his scientific interests focused on translational research in gastrointestinal oncology, specifically NET of the gastroenteropancreatic system. He was a co-founder of ENETS in 2004, he has also initiated the ENETS Centers of Excellence and developed the

CoE Excellence Academy Fellowship Program. He served 2004-2006 as ENETS first Chairman and is its Treasurer since 2008, He is a member of several international and national societies. He is an Assistant Editor of the official ENETS journal, Neuroendocrinology, and member of several Editorial Boards. He has published in numerous leading scientific peer-reviewed journals. He has been Congress President 2016 of the German Society of Gastroenterology (DGVS), AGA Institute representative and Chair for the 2016-2017 Program Committee GI ASCO, Member of the Steering Committee GI ASCO 2018.

Wyld, David – MBBS (HONS), FRACP, Associate Professor / Session 2 David Wyld is the Director of Medical Oncology at the Royal Brisbane and Women’s Hospital, Brisbane, Australia, an Associate Professor in the School of Medicine at The University of Queensland, and an Adjunct Associate Professor at Queensland University of Technology. He completed his oncology training in Brisbane, followed by a fellowship at St James’s University Hospital in Leeds, England, before returning to take up a consultant position in Brisbane. He has a strong clinical interest in gastrointestinal and neuroendocrine tumors and clinical trials, a specific research interest in neuroendocrine tumors and qualitative patient focused research, and an

ongoing involvement in education and training. He is currently a member of the Commonwealth Neuroendocrine Tumour Group (CommNETs) Executive and Project Oversight Committees.

Yao, James – MD, Professor / Session 1Clinical and translational research has been a focus of Prof. Yaos academic career. He has served as Principal Investigator on numerous phase I, II, and III clinical trials including leading five multi-center national or international clinical trials including the phase III RADIANT-3 study that advanced the standard of care for advanced pancreatic NETs and the phase III RADIANT-4 study that set the standard of care for lung and GI NETs. He also serves on the NCI Investigational Drug Steering Committee, Investigational Drug Steering Committee Coordinating Team, and as Past-Chair of NCI Neuroendocrine Taskforce. Dr. Yao has a strong interest in novel

clinical trial designs as well as biomarker development. He is also a Founding Member and Past-Chair of North American Neuroendocrine Tumor Society.

Meet the Faculty

SC

IEN

TIF

IC P

RO

GR

AM

63

Faculty List

Faculty List

Jorge Barriuso GBRDetlef Bartsch GEREric Baudin FRAJürgen Becker GERLisa Bodei USAMette Borre DENCatherine Bouvier GBRAndrea Califano USAJaume Capdevila ESPMartyn Caplin GBRJie Chen CHNAlexa Childs GBRMauro Cives ITAPaul Coffey GBRGianfranca Corna ITAAnne Couvelard FRAJoakim Crona SWEJoseph Davar GBRPhilippa Davies GBRWouter W. de Herder NEDGianfranco Delle Fave ITAAlban Denys SUIJulia Drewes USABarbro Eriksson SWEMassimo Falconi ITANicola Fazio ITADiego Ferone ITAAndrea Frilling GBRStefan Fröhling GERRocio Garcia-Carbonero ESPWanda Geilvoet NEDSimona Glasberg ISRVera Gorbunova RUSEnrique Grande ESPDavid Gross ISRAshley Grossman GBRRon Hollander USARobert Jensen USAGregory Kaltsas GREReza Kianmanesh FRAMichelle Kim USAUlrich Knigge DENTeodora Kolarova BULBeata Kos-Kudła POL

Ben Lawrence NZLCôme Lepage FRASimone Leyden AUSJosh Mailman USAElettra Merola GERTim Meyer GBRIrvin Modlin USAGuillaume Nicolas SUIBruno Niederle AUTKjell Öberg SWEDermot O’Toole IRLMauro Giulio Papotti ITAStefano Partelli ITAAndreas Pascher GERMarianne Pavel GERMarc Peeters BELChristodoulos Pipinikas GBRDeborah Pitfield GBRLise Munk Plum DENVikas Prasad GEREric Raymond FRAGuido Rindi ITAAnja Rinke GERMark Rubin SUIPhilippe Ruszniewski FRARamon Salazar ESPAldo Scarpa ITAJean-Yves Scoazec FRASimron Singh CANHalfdan Sorbye NORRaj Srirajaskanthan GBRChristina Thirlwell GBREva Tiensuu Janson SWEChristos Toumpanakis GBRJuan Valle GBRDirk Van Genechten BELMarco Volante ITAKate Wakelin AUSStaffan Welin SWETara Whyand GBRBertram Wiedenmann GERDamian Wild SUIDavid Wyld AUSJames Yao USA

SC

IEN

TIF

IC P

RO

GR

AM

64 *The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.

Abstract Titles

The titels of all approved abstracts include first authors and are listed here:

A. BASIC SCIENCE - SIGNALING PATHWAYS, RECEPTORS, BIOMARKERS(A01)* Bresciani G et al. Study of Cell Cycle Protein Expression Pattern in Bronchial Carcinoids: A New Potential Target for Medical Therapy?(A02) Briest F et al. Analysis of Gene Expression Patterns of Rectum Neuroendocrine Tumors (NET) Versus Healthy Tissue Reveals Alterations in the MAPK and WNT Signaling Pathways(A03) Briest F et al. Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine(A04) Cella CA et al. Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus(A05) Gantenbein N et al. Are eIFs Ingredients for Neuroendocrine Tumorigenesis?(A06) Grötzinger C et al. Identification and Validation of the Angiotensin II Receptor Type 1 as a Possible Anti-Cancer Target in Neuroendocrine Tumors(A07) Grötzinger C et al. Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells(A08) Gurevich L et al. Expression of Somatostatin Receptors in Neuroendocrine Tumors of the Lungs with Various Degrees of Malignancy(A09) Herrera-Martínez AD et al. Ghrelin O-Acyltransferase (GOAT) Enzyme and Ghrelin Receptor GHSR1a as Putative Prognosis Markers and Therapeutic Targets in Gastroenteropancreatic Neuroendocrine Tumors(A10) Ji M et al. Long Non-Coding RNA H19 Promotes Malignant Proliferation and Metastasis in Pancreatic Neuroendocrine Neoplasms(A11) Milione M et al. Stromal Immune Contexture Predicts Disease-Free Survival in Gastro-Entero- Pancreatic Neuroendocrine Neoplasms (GEP-NENs)(A12) Na H et al. Decreased Serum Amyloid A1 as Potential Diagnostic Marker for Gastro-Entero- Pancreatic Neuroendocrine Neoplasms (A13) Napolitano M et al. IMMUNeOCT Study: The Role of Octreotide LAR in Modulating the Immune Response in Patient with Neuroendocrine Tumors. EudraCT Number 2017-001613-83(A14) Pedraza-Arévalo S et al. Potential Role of SST5TMD4-Derived Peptides in the Malignancy of Neuroendocrine Tumors and Other Endocrine-Related Cancer Cells(A15) Qiu F et al. 177Lu-TOC Inhibits Cell Proliferation by Inducing Autophagy and G2/M Cell Arrest in Neuroendocrine Prostate Cancer Cell(A16) Romano D et al. Differential Signalling Pathways Drive Therapeutic Resistance in Neuroendocrine Tumors(A17) Sättele R et al. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Receptor Expression in Patients with Neuroendocrine Neoplasia(A18) Tsolakis A et al. Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?(A19) Vesely C et al. Systematic Evaluation of the Immune Microenvironment of Neuroendocrine Tumors (NET)(A20) Vitali E et al. The Anticancer Mechanism of Metformin in Pancreatic Neuroendocrine Tumor Cells(A21) Zhang Y et al. Expression and Clinical Significance of Vascular Endothelial Growth Factor D in Gastroenteropancreatic Neuroendocrine Neoplasms (A22) Zhang Y et al. Expression and Clinical Significance of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Phospho-VEGFR3 in Gastroenteropancreatic Neuroendocrine Neoplasms

B. BASIC SCIENCE - GENETICS, EPIGENETICS, MIRNAS, OMICS(B01) Arvidsson Y et al. miRNA Expression Defines Novel Subgroups of Small Intestinal Neuroendocrine Tumors (B02) Boons G et al. Genome-Wide DNA Methylation Profiling of Pancreatic Neuroendocrine Tumors(B03) Capdevila J et al. BRAF-V600E Driven Mutations in Grade 3 Neuroendocrine Carcinomas of Colon Origin: Results from Genomic/Epigenomic Profilings and Patient-Derived Mouse Model(B04) Cros J et al. Genomic and Transcriptomic Characterization of Aggressive Well Differentiated Pancreatic Neuroendocrine Tumors (WD PanNET)

OA

PW

OA

PW

OA

PW

OA

OA

SC

IEN

TIF

IC P

RO

GR

AM

65Legend: Selected for: Oral Abstract OA / Presidential Abstract PA / Poster Walks PW

Abstract Titles

(B05) Cros J et al. Mitochondrial or Aerobic Glycolysis Oriented Metabolism May Define Pancreatic Neuroendocrine Tumors (PanNET) Resistance to mTOR-Targeting Therapies(B06) Di Domenico A et al. Epigenetic Changes in DAXX and/or ATRX Negative Pancreatic Neuro- Endocrine Tumors(B07) Fatima A et al. Finding the Ways to Determine the Prognosis of Pulmonary Carcinoids with Certain Genes/Markers in Pakistan(B08) Hu Y et al. Retrospective Analysis of Gastroenteropancreatic Neuroendocrine Neoplasms and the Role of GSK-3β Expression in Neuroendocrine Neoplasms(B09) Jian-an B et al. Analysis of the Proteomics of Serum Circulating Exosomes in Gastro-Entero- Pancreatic Neuroendocrine Neoplasms (B10) Lawrence B et al. A Novel Classification of Pancreatic Neuroendocrine Tumors (pNETs) Guided by Genomics(B11) Lin LY et al. Endocan Expression Is Correlated with Poor Progression-Free Survival in Patients with Pancreatic Neuroendocrine Tumors(B12) Manoharan J et al. Chemoprevention with Enalapril and Aspirin in Men1(+/T) Knockout Mouse Model(B13) Pea A et al. Genetic Analysis Identifies Subgroups of Small Well-Differentiated Pancreatic Neuroendocrine Tumors with Different Risk for Liver Metastases(B14) Robb T et al. Enhancing Diagnostic Precision Through Combined Genomic and Histopathological Analysis of Pancreatic Neuroendocrine Tumors(B15) Robb T et al. Merkel Cell Carcinomas in New Zealand: Virus or Ultra Violet?(B16) Tirosh A et al. High Rate of Copy-Number Alterations in Gastrointestinal and Pancreatic Neuroendocrine Tumors with Unidentified Driver Mutations(B17) Vandamme T et al. Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors(B18) Wei Y et al. Screening of Differentially Expressed Genes in Gastric Neuroendocrine Neoplasms Based on Human Transcriptome Array(B19) Yang KC et al. Molecular Characterization of Primary and Metastatic Pancreatic Neuroendocrine Tumors

C. BASIC SCIENCE - IN VITRO MODELS, TUMOR GROWTH, CTCS(C01) Blazevic A et al. The Effect of Temozolomide on Pancreatic Neuroendocrine Tumors in Vitro and Role of MGMT and MMR System in Temozolomide Resistance(C02) Briest F et al. The BON-SSTR2 Chicken Chorioallantoic Membrane (CAM) Model for the Analysis of Lu-17-DOTATOC Sensitizing Agents(C03) Childs A et al. Single Cell Copy Number Variation Analysis (CNV) of Circulating Tumor Cells (CTCs) in Neuroendocrine Tumor (NET) Patients(C04) Dayton T et al. Using Adult Stem-Cell Derived Organoids to Model Neuroendocrine Tumor Growth(C05) Herrera-Martínez AD et al. Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture(C06) Herrera-Martínez AD et al. Potential Effects of Ketoconazole on ACTH-Producing and Non-ACTH- Producing Neuroendocrine Tumors(C07) Hofving T et al. The Neuroendocrine Phenotype, Genomic Profile, and Therapeutic Sensitivity of GEPNET Cell Lines(C08) Martínez-López A et al. Preclinical Testing of SSA Compounds in a Model of Pancreatic Neuroendocrine Tumors to Optimize Scheduling and Drug Exposition(C09) Matrood S et al. Autophagy Process in Pancreatic Neuroendocrine Tumor Cells(C10) Rizzo FM et al. CXCR4 Expression on Circulating Tumor Cells (CTCs) and Their Association with Bone Metastases in Patients with Neuroendocrine Tumors (NET)(C11) Sami M et al. Epigenetic Modulation of Autophagy in Pancreatic Spheroid Cells(C12) Schrader J et al. Development of Pre-Clinical NEN Models – Limitations and Opportunities(C13) Sposito T et al. Histone Replacement in Cancer: Dissecting the Role of H3.3 Chaperones in Pancreatic Tumorigenesis(C14) Zhang Y et al. Preliminary Evaluation of Influence of Different Targeted Drugs of Vascular Endothelial Growth Factor Signaling Pathway on the Proliferation of Neuroendocrine Neoplasm Cell Lines

PA

OA

PW

PW

PW

PW

OA

OA

OA

SC

IEN

TIF

IC P

RO

GR

AM

66 *The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.

Abstract Titles

D. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - REGISTRIES, NATIONWIDE AND REGIONAL SURVEYS(D01) Apostolidis L et al. Treatment Outcomes of Patients with Mixed Neuroendocrine Non- Neuroendocrine Neoplasms (MiNEN)(D02) Ashoka Menon V et al. Neuroendocrine Tumors: An Australian Experience(D03) Athar A et al. Recognition of Primary Neuroendocrine Tumors - A Challenge(D04) Banz S et al. First Patient Survey about Tumor - Associated Fatigue in NEN(D05) Berthon A et al. Direct Cost of Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Relation to Time Since Diagnosis Shows Growing Importance of Somatostatin Analogues (SSA)(D06) Berthon A et al. Long-Acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden(D07) Borbath I et al. The ENETS Registry: First Results of a Collaborative Effort Including over 12.000 Patients with Neuroendocrine Neoplasms (NENs) from 7 European Countries(D08) Cai W et al. Pattern and Risk Factors for Distant Metastases in Gastrointestinal Neuroendocrine Neoplasms: A Population-Based Study(D09) Carrillo D et al. Neuroendocrine Tumors in the Chilean Population(D10) Cavalcoli FA et al. Thrombotic Risk in Gastroenteropancreatic Neuroendocrine Tumors: A Single Centre Experience(D11) Chatzellis E et al. Endocrine Paraneoplastic Syndromes in Patients with Neuroendocrine Neoplasms(D12) Chiloiro S et al. Diagnostic and Clinical Management of Pancreatic Neuroendocrine in MEN1 Syndrome(D13) Chiloiro S et al. Screening Benefits in MEN1-Associated Pituitary Adenomas(D14) Davies P et al. Current Educational Strategies Used by Nurses Caring for NET Patients: Electronic Survey across 25 Countries(D15) Desai G et al. Trends in Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in India: A Report of Multicentre Data from a Web Based Registry(D16) El Chami A et al. Single-Institutional Review of Non-Pancreatic GI Neuroendocrine Tumors(D17) Fan Y et al. Retrospective Analysis of 228 Digestive System Neuroendocrine Tumor Patients from the Northwest of China(D18) Fan J et al. The Trend of Using CT to Diagnose the Gastroenteropancreatic Neuroendocrine Neoplasms: Results of a Nation-Wide Retrospective Epidemiology Study in China(D19) Fatima A et al. Finding the Options of Good Prognosis for Ampullary Neuroendocrine Tumors(D20) Fijalkowski R et al. Carcinoid Syndrome Open Questions – Evaluations from a Real Life Setting (D21) Frizziero M et al. Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumour Society Centre of Excellence(D22) Gaasvik L et al. Data on Healthcare Resource Utilization (HCRU) and Treatment Modalities in Patients (Pts) with Advanced (adv), Well-Differentiated (WD) Neuroendocrine Tumors (NETs) of Gastrointestinal (GI) or Lung Origin in Finland(D23) Galanopoulos M et al. Reassessment of Risk Factors Associated with Locoregional Lymph Nodal Metastases in Well-Differentiated Appendiceal Neuroendocrine Neoplasms(D24) Gao H et al. Is the Classification of Functioning-PanNET/Non-Functioning PanNET Properly? Insulinoma/Non-Insulinoma Is More Suitable to Distinguish the Clinicopathological and Prognosis Difference of Localized Insulinoma(D25) Gao S et al. The Latest Exploration of Staging and Prognostic Classification for Pancreatic Neuroendocrine Tumors(D26) Genc C et al. Ki67 to Predict Recurrence and Survival of Pancreatic Neuroendocrine Tumors(D27) Genus T et al. 1-Year Survival Rates for Neuroendocrine Tumor Patients in England(D28) Genus T et al. Incidence and Prevalence of Neuroendocrine Tumors in England(D29) Genus T et al. Metachronous Primary Cancers in Neuroendocrine Tumor Patients(D30) Giannone F et al. Incidental Histological Diagnosis of Small Pancreatic Neuroendocrine Tumors: Are We Underestimating Their Incidence?

OA

SC

IEN

TIF

IC P

RO

GR

AM

67Legend: Selected for: Oral Abstract OA / Presidential Abstract PA / Poster Walks PW

Abstract Titles

(D31) Grimaldi F et al. Vitamin D, Bone Mineral Density and Fracture Risk Assessment in Patients with Neuroendocrine Tumors(D32) Hayes AR et al. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Characterisation of Prevalence and Prognosis in the Pulmonary Carcinoid Population(D33) Issaeva S et al. Predictive Markers of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)(D34) Jimenez-Fonseca P et al. Neuroendocrine Tumors Committee of Reference Hospital: Decision- Making Process on the Diagnostic and Therapeutic Approach to Patients with Neuroendocrine Tumors(D35) Khalimova Z et al. The Results of Screening of the Syndrome of Cushing in the Republic of Uzbekistan(D36) Komarova L et al. Retrospective Epidemiologic Study of Medullary Cancer of Thyroid Gland in Hospital – Based Registry in Moscow Cancer Centre(D37) Lal DPCK et al. Clinical Significance of Incidental Detection of Appendicular Neuroendocrine Tumors in Sri Lanka(D38) Li YL et al. Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: 400 Cases of Multicenter Retrospective Analysis(D39) Lim S et al. Nutritional Assessment and Vitamin Deficiencies in Patients with NETs(D40) Liu Z et al. A Retrospective Analysis of 344 Cases with Neuroendocrine Neoplasms(D41) Liu Q et al. Assessment of Quality of Life in Chinese Patients with Gastroenteropancreatic Neuroendocrine Tumors(D42) Lyu Y et al. Risk Factors Affecting Prognosis in Metachronous Liver Metastases from WHO Classification G1 and G2 Gastroenteropancreatic Neuroendocrine Tumors after Initial R0 Surgical Resection(D43) Mao W et al. Analysis of Clinical Pathology Features and Prognostic Factors of 20 Patients with Appendiceal Neuroendocrine Neoplasms(D44) Mao W et al. Development of a Predictive Prognostic Nomogram for the Neuroendocrine Carcinomas of Rectum Based on a Large Population-Based Exploration(D45) Masini G et al. Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and How?(D46) Massironi S et al. Can Neutrophil-to-Lymphocyte Ratio (NLR) Predict Clinical Outcomes of Pancreatic Neuroendocrine Tumors (PanNETs)?(D47) Massironi S et al. Eterogeneity of Duodenal Neuroendocrine Tumors: A Multi-Centre Experience in Italy(D48) Maurissen I et al. The Impact of NETwerk on the Multidisciplinary Tumor Boards(D49) Mintziras I et al. Are Current ENETS Guidelines for Surgery of Small (< 2cm) Pancreatic Neuroendocrine Neoplasms Implemented in German Surgical Community?(D50) Mintziras I et al. Perioperative Outcomes of Surgery for Pancreatic Neuroendocrine Neoplasms in Germany(D51) Modica R et al. Survival and Prognosis in Patients with Duodeno-Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome(D52) Narimova G et al. The Condition of Carbohydrate Exchange in New Revealed Patients with Cushing’s Syndrome(D53) Nayroles G et al. Prevalence of Carcinoid Syndrome (CS) in the European Union (EU)(D54) Parker K et al. Approaching NETs from Many Angles: A Medical Research Paradigm to Challenge New Zealand’s Research Traditions(D55) Parker K et al. The NETwork! Registry Suggests Increasing Incidence in a National Study of Neuroendocrine Cancer in New Zealand (NZ)(D56) Qiu XD et al. Clinicopathological Features of 63 Cases with Type 3 Gastric Neuroendocrine Tumors(D57) Reynolds M et al. Remote Tracking of Symptoms, QoL and Wellbeing within the New Wales NET Service(D58) Riechelmann R et al. High Hepatic Tumor Burden and History of Cardiovascular Comorbidities Are Associated with Carcinoid Heart Disease: A Multicenter and Multinational Study(D59) Sarabi M et al. Patient Survey Devoted to Characterizing Experience and Expectations of Patients with Neuroendocrine Tumors (NET)

SC

IEN

TIF

IC P

RO

GR

AM

68 *The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.

Abstract Titles

(D60) Sedlackova E et al. Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) in the Czech NEN Registry 2009-2016: Histologic Spectrum and Clinicopathological Features(D61) Stemann Lau T et al. The Risk of Secondary Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Tumors – A Nationwide Population Based Study(D62) Uri I et al. Diagnosing and Managing MEN1-Related pNETs in Israel: A Specialist Center Experience(D63) Urmanova Y et al. Frequency, the Characteristic of Diseases of Thyroid Gland at Children and Teenagers According to Negotiability during 5 Years(D64) Urmanova Y et al. The Frequency of Patients with Giant Pituitary Tumors from Retrospective Data(D65) van Leeuwaarde R et al. Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors?(D66) Vandamme T et al. Excellent Survival Outcomes for NET Patients Treated within NETwerk, a Collaborative ENETS Center of Excellence(D67) Vesterinen T et al. Prognostic Factors of Pulmonary Carcinoid Tumors(D68) Whyand T et al. Self-Reported Side Effects in Neuroendocrine Tumor (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses(D69) Winkler EC et al. Financial Toxicity in Patients with Neuroendocrine Tumor Disease. A so far Underestimated „Side Effect“ of Cancer in Germany?(D70) Wyld D et al. How the Rare See Their Care: Perceptions of Care and Patient Reported Outcomes in People Living with Neuroendocrine Tumors(D71) Yu P et al. Clinicopathologic Characteristics of Chinese Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: Results of a Nation-Wide Retrospective Epidemiology Study(D72) Zandee W et al. Evaluation of Multidisciplinary Tumor Board Decisions in the Management of Neuroendocrine Tumors: Impact of Expert Centers(D73) Zhang P et al. A Single-Center Retrospective Analysis of Clinicopathological Characteristics of Gastroenteropancreatic Large Cell Neuroendocrine Neoplasms (GEP-LCNEC)(D74) Zhang P et al. Clinical Study on High-Risk Factors Leading to Recurrence of Well-Differentiated Pancreatic Neuroendocrine Neoplasms after Surgery(D75) Zhang Y et al. Clinicopathological Features and Prognosis of Colonic Neuroendocrine Neoplasms in Different Races(D76) Zhang Y et al. The Exact Prognostic Significance of Lymphatic Metastasis of Jejunoileal Neuroendocrine Tumors(D77) Berthon A et al. Long-Acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden

E. PATHOLOGY - GRADING, STAGING(E01) Andreasi V et al. The Number of Positive Nodes Accurately Predicts Recurrence after Pancreaticoduodenectomy for Nonfunctioning Neuroendocrine Neoplasms(E02) Andreassen M et al. Immunohistochemical Profiles in 81 Patients with Resected Insulinomas(E03) Boeck I et al. Poorly Differentiated Neuroendocrine Carcinomas of the Colon: A Clinicopathological Study(E04) Carmona-Bayonas A et al. Expanding the WHO 2017 Classification to Gastrointestinal Tumors: Real-World Data from the R-GETNE Registry(E05) Delektorskaya V et al. Clinicopathological Features of the High Grade Pancreatic Neuroendocrine Neoplasms (E06) Dhall D et al. Well-Differentiated Neuroendocrine Lesions in Inflammatory Bowel Disease (E07) Furnace M et al. High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?(E08) Gao H et al. Novel Recurrence Risk Stratification of Resected Pancreatic Neuroendocrine Tumor(E09) Luong TV et al. Phosphohistone H3 (PHH3) Immunohistochemical Staining Outperforms Conventional H&E Mitotic Count in Classifying Pulmonary Carcinoids(E10) Merola E et al. Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?

SC

IEN

TIF

IC P

RO

GR

AM

69Legend: Selected for: Oral Abstract OA / Presidential Abstract PA / Poster Walks PW

Abstract Titles

(E11) Milione M et al. Ki-67 and Presence of Liver Metastases Predicts Progression in Pancreatic Neuroendocrine Neoplasms (pNENs)(E12) Rizza S et al. EUS-FNA in the Diagnosis of Pancreatic Neuroendocrine Tumors and Accuracy of Ki- 67 Measurement on Cytological Samples: The Turin Experience(E13) Xu J et al. Intrinsic Contact between T Classification and N Classification in Resected Well- Moderate Differential Locoregional Pancreatic Neuroendocrine Neoplasms

F. BIOMARKERS(F01) Atanasov G et al. Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors(F02) Athar A et al. Significance of Biochemical Testing in Pancreatic Neuroendocrine Tumors(F03) Bajciova V et al. When Is Right Hemicolectomy Really Indicated for Pediatric Appendiceal NETs? (F04) Chan DL et al. Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials(F05) Dam G et al. A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors(F06) Genc C et al. The Clinical Value of Circulating Transcript Analysis (NETest) during Follow-Up of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors(F07) Grigorescu RR et al. Prognostic Value of the Different Pre-Treatment Biomarkers for Patients with Neuroendocrine Tumors(F08) Kjellman M et al. Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study(F09) Kruljac I et al. The Role of Subcutaneous Octreotide Suppression Test in Detecting Patients with Neuroendocrine Neoplasms: A Pilot Study(F10) Liu E et al. Assessment of the Clinical Utility of the NETest in a US Registry-Based Study(F11) Mecca C et al. Tumor Microenvironment in Merkel Cell Carcinoma: Association with Merkel Cell Polyomavirus and Clinico-Pathological Features in a Retrospective Cohort Study(F12) Moschouris P et al. The Association between Gastrin and Glucose Serum Concentration in Hypergastrinemic Patients with Gastric Neuroendocrine Tumors Type 1 and ECL-Cells Hyperplasia(F13) Partelli S et al. Circulating Neuroendocrine Gene Transcripts (NETest) Decrease Early after Radical Surgery: Preliminary Results of a Prospective Study(F14) Rosiek V et al. Assessment of the Serum Levels of the Soluble Vascular Cellular Adhesion Molecule-1 (sVCAM-1) in Patients with Neuroendocrine Neoplasms (F15) Rossi RE et al. Alpha-Fetoprotein in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Single Centre Study(F16) Rossi RE et al. Chromogranin A as a Marker in the Follow-up of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). A Systematic Review(F17) Sadanandam A et al. Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations(F18) Tirosh A et al. 24 Hour Urinary 5-Hydroxyindoleacetic Acid Levels in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors(F19) Vladova P et al. Prognostic Value of Immunohistochemical Expression of Somatostatin Receptors (SS-R2 and SS-R5) in the Gastroenteropancreatic Neuroendocrine Tumors, Diagnosed in the University Hospital of Pleven, Bulgaria, from the Period 2010 to November 2017

G. IMAGING AND INTERVENTIONS (RADIOLOGY, ENDOSCOPY)(G01) Antwi A et al. Comparison of Glucagon-Like-Peptide-1 (GLP-1) Receptor PET/CT, SPECT/CT and 3T MRI for the Localisation of Insulinomas: Evaluation of Accuracy in a Prospective Crossover Imaging Study(G02) Blazevic A et al. Progression of Mesenteric Metastasis in Small Intestinal Neuroendocrine Tumors(G03) Carmona-Bayonas A et al. Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)(G04) Chiloiro S et al. 99mTc-Colloid Scintigraphy in the Differential Diagnosis of Pancreatic NET

PW

OA

SC

IEN

TIF

IC P

RO

GR

AM

70 *The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.

Abstract Titles

(G05) Crona J et al. Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well- Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study(G06) Fehrenbach U et al. How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms(G07) Gao S et al. Transcatheter Arterial Chemoembolization Synergizes with Simultaneous Microwave Ablation in the Treatment of Unresectable Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastasis(G08) Gulati S et al. Linked Colour Imaging Increases the Diagnostic Yield of Type 1 Gastric Carcinoid(G09) Iorio J et al. Imaging Modality Depending on the Levels of Tumor Markers(G10) Janas K et al. 4D Ultrasound High Definition Flow with Spatio-Temporal Image Correlation in Evaluation of Neuroendocrine Liver Metastases – Preliminary Study(G11) Kieszko D et al. CT-Guided HDR Brachyterapy in Patients with Advanced Non-Resectable and Progressive NEN with Liver Bulky Disease. Pilot Study(G12) Lamarca A et al. Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients’ Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study(G13) Liu Y et al. Hepatic Tumor Burden Can Be Reduced Rapidly and Effectively by Trans-Arterial Embolization Combined with Systemic Therapy in Patients with Neuroendocrine Tumor Liver Metastasis (NETLM)(G14) Michałowska I et al. Carcinoid Heart Disease - Diagnostic Usefulness of Cardiac Computed Tomography – A Pilot Study(G15) Ronot M et al. Mechanisms of Main Pancreatic Duct Dilatation in Pancreatic Neuroendocrine Tumors (PanNETs): Radiopathologic Correlation(G16) Thiis-Evensen E et al. The RECIST Criteria Compared to Conventional Response Evaluation after Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasms(G17) Tsoli M et al. The Role of Magnetic Resonance Imaging and Endoscopic Ultrasound Imaging in the Diagnosis and Management of Pancreatic Neuroendocrine Tumors (pNET) in Patients with Multiple Endocrine Neoplasia Type 1 (MEN1)

H. MEDICAL TREATMENT - CHEMOTHERAPY SOMATOSTATIN ANALOGUES, INTERFERON(H01) Ali AA et al. Intravenous versus Oral Etoposide: Efficacy and Correlation to Clinical Outcome in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)(H02) Antonijoan Arbós RM et al. Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers(H03) Capdevila J et al. Prospective, Multi-Center, Open Label, Phase Study II of APOC, a New Controlled Release 15mg Octreotide Acetate, for the Treatment of Advanced NETs(H04) Ćwikła JB et al. Clinical Use of Lanreotide AG as Initial Therapy in Patients with Advanced, Non- Resectable Well (G1) and Moderate (G2) Differentiated Pancreatic Neuroendocrine Neoplasms (p-NEN)(H05) Dal Buono A et al. Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens(H06) Daskalakis K et al. Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors(H07) Davies P et al. Audit of a New Nurse-Led Non-Medical Prescribing (NMP) Clinic for Systemic Anti- Cancer Agents (SACTs)(H08) De Divitiis C et al. Efficacy and Toxicity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms(H09) Faggiano A et al. Therapeutic Sequences in Patients with G1-G2 Neuroendocrine Tumors (NETs): An Observational, Multicentre, Prospective/Retrospective Study(H10) Geldenhuys D et al. Interim Analyses LANREL07484: Quality of Life in Patients with Symptomatic Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa(H11) Geldenhuys D et al. Interim Analyses LANREL07484: Response to Treatment and Self-Reported Satisfaction in Symptoms in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa

OA

SC

IEN

TIF

IC P

RO

GR

AM

71Legend: Selected for: Oral Abstract OA / Presidential Abstract PA / Poster Walks PW

Abstract Titles

(H12) Giuffrida D et al. Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis(H13) Ichikawa Y et al. Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy(H14) Klink A et al. A Comparison of Retrospective Database Analysis with Chart Review in Patients Receiving Somatostatin Analog (SSA) in Neuroendocrine Tumors (NETs)(H15) Kolasińska-Ćwikla A et al. Efficacy of Octreotide LAR in Treatment of Naive Patients with Advanced, Non-Resectable Well and Moderate Differentiated Pancreatic Neuroendocrine Neoplasms (p-NENs)(H16) Lamarca A et al. International Survey of Clinical Practice Exploring Use of Platinum-Etoposide Chemotherapy for Extra-Pulmonary High Grade Neuroendocrine Carcinoma (EP-G3-NEC)(H17) Laskaratos F et al. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs)(H18) Laskaratos F et al. Predictors of Antiproliferative Effect of Lanreotide Autogel (LA) as First-Line Therapy for Advanced Neuroendocrine Tumors (NETs)(H19) Pavel M et al. Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study(H20) Pellat A et al. Perioperative Chemotherapy in Resectable Neuroendocrine Carcinomas of the Digestive Tract(H21) Puliafito I et al. Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience(H22) Sakamoto Y et al. Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan(H23) Smiroldo V et al. Efficacy of Oral Chemotherapy with Capecitabine and Temozolomide (Captem) in Patients with Metastatic Neuroendocrine Tumors (NETS). A Single-Institution Experience(H24) Wang X et al. Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors(H25) Zhang Y et al. Capecitabine/Temozolomide (CAPTEM) Regimen in the Treatment of Advanced Neuroendocrine Neoplasms: A Single-Center Retrospective Study in China

I. MEDICAL TREATMENT - TARGETED THERAPIES(I01) Dasari A et al. A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors(I02) Fatima A et al. Do We Need Hormonal Therapy for Pancreatic Neuroendocrine Tumors? An Effort to Reduce the Size of PanNETs(I03) Fazio N et al. Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials(I04) Fejzibegovic N et al. Activity of Bevacizumab in Neuroendocrine Neoplasms(I05) Jennifer C et al. Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors(I06) Jimenez-Fonseca P et al. Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)(I07) Kuznetsova A et al. Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors(I08) Lombard-Bohas C et al. OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)(I09) Rinzivillo M et al. Sunitinib in Patients with Pre-Treated Pancreatic Neuroendocrine Tumors: A Real- World Study (I10) Yao JC et al. ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly- Differentiated GEP NEC Who Have Progressed on Prior Treatment

PW

PW

PW

SC

IEN

TIF

IC P

RO

GR

AM

72 *The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.

Abstract Titles

J. MEDICAL TREATMENT - OTHERS, NOT SPECIFIED(J01) Al-Toubah T et al. Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors(J02) Bei X et al. Clinical Characteristics and Prognostic Analysis of 14 Patients with Gastric Mixed Adenoneuroendocrine Carcinoma(J03) Bongiovanni A et al. Metastatic Neuroendocrine Neoplasia Treatments in over 70 Years Old Patients: A Retrospective Outcome Analysis(J04) Byakhova M et al. The Role of Diagnostic Biopsy to Determine the Treatment Tactics of Patients with Lung Tumors of Different Histogenesis. The Experience of a Single Multidisciplinary Center for the Period 2014-2017 Years(J05) Custodio A et al. On-going Evaluation of the Use of Resources and the Costs (UR/C) Associated with Controlled or Uncontrolled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine Tumours (NETs): RECOSY Study Design(J06) Dillon J et al. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome(J07) Fatima A et al. Identifying the Severity of Psychosocial Symptoms among Patients Diagnosed with Pancreatic Neuroendocrine Tumor. Do We Really Need Emotional Support Groups?(J08) Gallego J et al. Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study(J09) Gueguen D et al. OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Neuroendocrine Tumors Starting Lanreotide – Study Design(J10) Hernando J et al. Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial/GETNE 1601)(J11) Ivanov A et al. Clinical and Morphological Features of Extrapulmonary Small-Cell Cancer(J12) Jia R et al. Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams(J13) Kaiser K et al. Patient and Clinician Perspectives on Symptom Priorities across the Spectrum of Neuroendocrine Tumors (NETs)(J14) Kennedy E et al. Exploring Nutrition Screening and Management Practices amongst Health Professionals Managing Patients with Neuroendocrine Tumors (J15) Kennedy E et al. Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumor: Preliminary Baseline Characteristics from the Nutrition in NETs Study(J16) Khan M et al. Development of a Patient-Centred Service for Neuroendocrine Tumors (NETs) in Wales: Population Based National Commissioning(J17) Kiesewetter B et al. Oral Ondansetron Offers Effective Symptomatic Bridging for Carcinoid Syndrome Refractory to Somatostatin Analogues(J18) Pevny S et al. Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status(J19) Safarova M et al. Menstrual Dysfunction in Women with Prolactinomas(J20) van Veenendaal LM et al. Safety and Efficacy of TAE and SIRT in NET Patients

K. NUCLEAR MEDICINE - IMAGING AND THERAPY (PRRT)(K01) Aalbersberg E et al. Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients with NETs(K02) Aalbersberg E et al. Parameters to Predict Overall Survival after PRRT – A Multivariate Analysis in 783 Patients(K03) Bodei L et al. Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker(K04) Braat A et al. International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors(K05) de Mestier L et al. Detection of Bone Metastases at FDOPA-PET in Small-Intestine (si)NET: Prevalence and Associated Factors

PW

SC

IEN

TIF

IC P

RO

GR

AM

73Legend: Selected for: Oral Abstract OA / Presidential Abstract PA / Poster Walks PW

Abstract Titles

(K06) Dureja S et al. 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience(K07) Huizing D et al. Short-Term Change in Symptoms and Adverse Events Evaluation after PRRT – First Experience after 56 Patients(K08) Kolasinska Cwikla A et al. PRRT in Hindgut and Cancer of Unknown Primary NEN(K09) Kong G et al. Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)(K10) Konsek SJ et al. Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Based on Clinical Follow-up and Results of NETest(K11) Ladwa R et al. Positron Emission Tomography (PET) Predictors of Tumor Response to Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors (NET)(K12) Ladwa R et al. Pretherapeutic Predictors of Tumor Absorbed Dosimetry in Radionuclide Therapy for Metastatic Neuroendocrine Tumors(K13) Ladwa R et al. Tumor Absorbed Dosimetry and Response of Radionuclide Therapy in Metastatic Neuroendocrine Tumor(K14) Liotsou T et al. Diagnostic Utility of ki67 as a Mean to Predict the Uptake of Functional Imaging Modalities in Patients with Neuroendocrine Neoplasms(K15) Liotsou T et al. Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity(K16) Mailman J et al. Education and Preparation for Nuclear Medicine Procedures in Neuroendocrine Tumor Patients(K17) Majala S et al. Nonfunctional Pancreatic Neuroendocrine Tumor (NF PNET) Imaging and Evaluation Using 18F-FDG and 68Ga- DOTANOC-PET/CT: Initial Data of a Prospective Study(K18) Picallo M et al. One Year Experience with Lutetium-DOTATATE for Disseminated NETs in the Gregorio Marañon Hospital(K19) Rottenburger C et al. Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N – Preliminary Proof of the Principle within the “Lumed” Study(K20) Skovgaard D et al. Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms: A Retrospective International Multicenter Study (K21) Steyn R et al. Does Somatostatin Receptor (SSR) Positive Tumor Volume Determined on Ga68 DOTANOC PET/CT in Patients with Paraganglioma (PGL)/Pheochromocytoma(PCC) Correlate with Biomarkers? An Explorative Study(K22) Strosberg J et al. Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors(K23) van der Zwan W et al. A Randomized Controlled Study Comparing Treatment of Gastro-Entero- Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine(K24) van der Zwan W et al. PFS and OS after Salvage Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors (GEP-NETs) – The Rotterdam Cohort(K25) Virgolini I et al. Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients with GEP-NETs(K26) Yan SX et al. Optimizing Reconstruction Algorithm to Improve Quality of Post-PRRT Yittrium-90 PET Scan (K27) Yordanova A et al. Efficacy of Adding Somatostatin Analogues to [177Lu] Lu-Octreotate as a Combination and Maintenance Therapy in Metastatic Neuroendocrine Tumors(K28) Yu J et al. The Correlation between 68Ga-DOTATATE PET/CT Results and Tumor Proliferation in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)

L. SURGICAL TREATMENT AND ABLATIVE THERAPIES(L01) Blazevic A et al. Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors(L02) Brighi N et al. Morphological Factors Related to Nodal Metastases in Neuroendocrine Neoplasms of the Appendix. A Multicenter Retrospective Study

PA

OA

OA

PW

SC

IEN

TIF

IC P

RO

GR

AM

74 *The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.

(L03) Clift AK et al. Appropriate Surgical Strategy in Appendiceal Neuroendocrine Tumors: Is Right Hemicolectomy Oncologically Justified or Overtreatment?(L04) Dai H et al. The Prognostic Impact of Primary Tumor Resection in Pancreatic Neuroendocrine Tumors with Synchronous Multifocal Liver Metastases(L05) Holmager P et al. Neuroendocrine Neoplasms of the Appendix: Characterization of 251 Patients Referred to the Copenhagen NET Centre of Excellence(L06) Malpaga A et al. Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Non Functioning Pancreatic Neuroendocrine Tumors: Outcome Analysis from 378 Consecutive Resections in a High-Volume Institution(L07) Mao W et al. A Matched-Pair Analysis of Conventional Surgical Methods versus Enucleation for Pancreatic Neuroendocrine Tumors(L08) Marchegiani G et al. The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-Trend and Outcome Analysis from 587 Consecutive Resections at a High-Volume Institution(L09) Masui T et al. A Comparison of Recurrence after Curative Resection between Pancreatic and Duodenal Neuroendocrine Tumors(L10) Milanetto AC et al. 35 Years of Experience in a Single Center on Distal Pancreatectomy for Neuroendocrine Tumors(L11) Milanetto AC et al. Health-Related Quality of Life Determinants in Swedish Patients after Surgery for Small Intestinal Neuroendocrine Tumors(L12) Milanetto AC et al. Pancreatic Involvement in Small Intestinal Neuroendocrine Tumors(L13) Milanetto AC et al. Pancreatic NET or Pancreatic Clear Cell Renal Cancer Metastases in Post- Nephrectomy Patients? (L14) Milanetto AC et al. Pancreatic NETs with Liver Metastases. Outcome of Surgically Treated Patients. A Single Center Experience(L15) Milanetto AC et al. Survival after Surgical Treatment of Small Intestinal Neuroendocrine Tumors with Liver or Peritoneal Metastases: 25 Years of Experience(L16) Muffatti F et al. Tumor Size Correlates with Grading in Nonfunctioning Pancreatic Neuroendocrine Tumors and Is Not Age-Dependent(L17) Piccioli AN et al. Predicting Resectability of Primary Tumor and Mesenteric Lumps in Patients with Small Intestine Neuroendocrine Tumors(L18) Ruzzenente A et al. Liver Resection for Neuroendocrine Tumors Liver Metastases in Transplantable Patients within the Milan Criteria(L19) Zubaryev M et al. The Laparoscopic Approach in the Surgical Treatment of the Gastric Neuroendocrine Tumors

M. NON DIGESTIVE NETS (BRONCHIAL, THYMIC, OTHERS) - DIAGNOSIS AND THERAPY(M01) Apostolidis L et al. Clinical Characteristics, Treatment Outcomes and Potential Novel Therapeutic Options for Patients with Prostatic Neuroendocrine Carcinoma(M02) Barlow J et al. Pulmonary Function Test Physiology and Progression in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia(M03) Castillo-Fernandez O et al. Primary Neuroendocrine Tumors of the Breast(M04) Groendahl V et al. Results of 252 Patients with Bronchopulmonary Neuroendocrine Tumors Treated at the Copenhagen NET Centre of Excellence(M05) Kasajima A et al. PD-L1 Expression and Its Clinical Relevance in Neuroendocrine Tumors of the Lung(M06) Li Q et al. Clinicopathologic Features and Treatment Outcome of 225 Newly Diagnosed Pulmonary Carcinoids: A Single Center Experience of 28 Years(M07) Martins Branco D et al. Large Cell Neuroendocrine Carcinoma of the Lung: Single-Centre Retrospective Cohort Study(M08) McFadyen R et al. Typical and Atypical Bronchial NETs with Advanced Disease: Incidence, Management and Survival(M09) Modlin I et al. Validation of a Blood-Based Biomarker Test for the Diagnosis and Management of Bronchopulmonary Neuroendocrine Tumors

Abstract Titles

OA

PW

SC

IEN

TIF

IC P

RO

GR

AM

75

(M10) Talbot D et al. A Comparison of Diagnostic and Management Pathways for Patients with Lung Neuroendocrine Tumors in ENETS Centres of Excellence vs Non-Accredited Centres in the UK: Results from the National Lung NET Pathway Project (‘LEAP’)

N. ENDOCRINE MALIGNANCIES (MTC, PHEOCHROMOCYTOMA) - DIAGNOSIS AND THERAPY(N01) Cai W et al. Clinical and Pathological Differences between NEC and Carcinoma of Esophagus: A Population Based Study(N02) Loh WJ et al. Sensitivity and Specificity of Insulin, C-Peptide and Nadir Glucose during 72 hr Supervised Fast in Diagnosis of Insulinoma(N03) Mansfield A et al. Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors(N04) Muñoz de Nova JL et al. Early Prognostic Factors in Medullary Thyroid Carcinoma(N05) Soczomski P et al. Pancreatic Neuroendocrine Tumor in Polish Population with MEN 1 Syndrome (N06) Zhang Y et al. Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma

Abstract Titles

Legend: Selected for: Oral Abstract OA / Presidential Abstract PA / Poster Walks PW

SC

IEN

TIF

IC P

RO

GR

AM

76

End of Scientific Program

ENETS Supported Study

CO

E W

OR

KS

HO

P

77

CoE - Centers of Excellence Workshop

Wednesday, 7 March 2018

The Centers of Excellence (CoE) Workshop Training Course is taking place within the framework of the 15th Annual ENETS Conference. Limited seats, prior online registration required.

Time: 10:15 - 14:00

Time Topic Room

ENETS Centers of Excellence Workshop Training Course 131

10:15 - 11:15 Registration

11:15 - 11:30 Introduction Overview: CoE Procedure Eva Tiensuu Janson, SWE Chair of the ENETS CoE Certification Program

11:30 - 12:45 Aims, Basic Principles and Definitions ENETS CoE – Certification Procedure • Application • Enrolment Fundamentals of the Requirements Catalogue Presentation of Selected Documents Questions Regine Reinstorf, GER Coordinator of the ENETS Certification Program for GSG ENETS – Cert

12:45 - 13:15 ENETS CoE – Certification Procedure • Audit Preparation “What Has to Be Done between Enrolment and Onsite Audit?“ • Questions Regine Reinstorf, GER

(Work & Lunch)

13:15 - 13:45 ENETS CoE – Certification Procedure • Onsite Audit • Deviations Regine Reinstorf, GER

13:45 - 14:00 Feedback and Questions Regine Reinstorf, GER Eva Tiensuu Janson, SWE

Coffee and tea will be offered during the entire workshop

SP

ON

SO

RS

& E

XH

IBIT

OR

S

78

Sponsors & Exhibitors

Industry - Sponsored Satellite Symposium I

How to Navigate the Labyrinth of Treatments in Neuroendocrine Neoplasms12:45 - 14:15, Thursday, 8 March 2018

Time Topic Room

12:45 - 12:55 Welcome and Introduction 112 Chair: Barbro Eriksson Uppsala University Hospital, Uppsala, Sweden

12:55 - 13:30 CASE STUDY 1: Pancreatic NENs Living with Pancreatic Neuroendocrine Neoplasms: Can We Improve the Patient Treatment Journey? Jennifer Chan Dana Farber Cancer Institute, Boston, USA Angela Lamarca The Christie NHS Foundation Trust, Manchester, UK

13:30 - 14:05 CASE STUDY 2: Carcinoid Syndrome Treating Patients with Carcinoid Syndrome. Do We Understand the Challenges? Simona Glasberg Hadassah Medical Center, Jerusalem, Israel Rachel Riechelmann A.C. Camargo, São Paulo, Brazil

14:05 - 14:15 Key Learnings, Summary and Close Barbro Eriksson Uppsala University Hospital, Uppsala, Sweden

Come and join us as we explore treatment options in neuroendocrine neoplasms, with a focus on pancreatic NENs and carcinoid syndrome. Our expert faculty will guide you through interactive case studies and

you can vote in the clinical decision making process. Choose the right path for your patients.

Lunchboxes will be provided

SP

ON

SO

RS

& E

XH

IBIT

OR

S

79

Industry - Sponsored Satellite Symposium II

Advancing the Care of Patients with Neuroendocrine Tumors:A State of the Art CONVERSATION with NET Experts

18:50 - 20:20, Thursday, 8 March 2018

Time Topic Room

18:50 - 18:55 Welcome and Introductions 112 Chair: Simron Singh Oncologist, University of Toronto, Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada

18:55 - 19:05 Diagnostic Challenges and Improvements: The Importance of Biological Classification vs Primary Tumor to Guide Treatment Selection Kjell Öberg Professor Emeritus Endocrine Oncology, Uppsala University, Uppsala, Sweden

19:05 - 19:20 Discussion and Case Challenge All Faculty

19:20 - 19:30 Advancing Patient Care: The Evolving Treatment Algorithm for Advanced NET Jaume Capdevila Oncologist, Gastrointestinal and Endocrine Tumor Unit, Vall d’Hebron University Hospital, Barcelona, Spain

19:30 - 19:45 Discussion and Case Challenge All Faculty

19:45 - 19:55 Improving the NET Patient Journey: Quality of Life in the Age of Targeted Treatment Simron Singh Oncologist, University of Toronto, Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada

19:55 - 20:10 Discussion and Case Challenge All Faculty

20:10 - 20:20 Discussion and Case Challenge Simron Singh Oncologist, University of Toronto, Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada

Sponsors & Exhibitors

SP

ON

SO

RS

& E

XH

IBIT

OR

S

80

Sponsors & Exhibitors

ENETS gratefully acknowledges the generous support of the sponsors

Platinum Sponsor Conference App Sponsor

Legacy Sponsor

& Bronze Sponsors

Conference App Sponsor

Industry - Sponsored Satellite Symposia

Symposium I How to Navigate the Labyrinth of Treatments in Neuroendocrine Neoplasms Supported by IPSEN Thursday, 8 March 2018, 12:45 - 14:15, Room 112

Symposium II Advancing the Care of Patients with Neuroendocrine Tumors: A State of the Art CONVERSATION with NET Experts Supported by Novartis Oncology Thursday, 8 March 2018, 18:50 - 20:20, Room 112

SP

ON

SO

RS

& E

XH

IBIT

OR

S

81

Sponsors & Exhibitors

SP

ON

SO

RS

& E

XH

IBIT

OR

S

82

Sponsors & Exhibitors

SP

ON

SO

RS

& E

XH

IBIT

OR

S

83

Sponsors & Exhibitors

Patient Advocacy ENETS kindly thanks the patient advocacy organizations for their presence and participation during the 15th Annual ENETS Conference 2018.

Exhibitors ENETS greatly thanks all the exhibitors for their presence and participation during the 15th Annual ENETS Conference 2018 and for sharing their knowledge, expertise and resources.

Non-Profit Organizations ENETS also greatly appreciates and gives thanks to the presence and participation by the non-profit organizations during the 15th Annual ENETS Conference 2018.

Exhibitors, Patient Advocacy & Non-Profit Organizations

SP

ON

SO

RS

& E

XH

IBIT

OR

S

84

Sponsors & Exhibitors

SP

ON

SO

RS

& E

XH

IBIT

OR

S

85

Sponsors & Exhibitors

SP

ON

SO

RS

& E

XH

IBIT

OR

S

86

Sponsors & Exhibitors

SP

ON

SO

RS

& E

XH

IBIT

OR

S

87

Sponsors & Exhibitors

Pfizer Oncology is committed to pursuing innovative treatments that have a

meaningful impact on those living with cancer. As a leader in oncology speeding

cures and accessible breakthrough medicines to patients, Pfizer Oncology is helping

to redefine life with cancer. Our strong pipeline of biologics, small molecules and

immunotherapies, one of the most robust in the industry, is studied with precise

focus on identifying and translating the best scientific breakthroughs into clinical

application for patients across a wide range of cancers. By working collaboratively

with academic institutions, individual researchers, cooperative research groups,

governments and licensing partners, Pfizer Oncology strives to cure or control cancer

with its breakthrough medicines. Because Pfizer Oncology knows that success in

oncology is not measured solely by the medicines you manufacture, but rather by the

meaningful partnerships you make to have a more positive impact on people’s lives.

PP-ONC-ESP-0068, date of preparation: January 2018

SP

ON

SO

RS

& E

XH

IBIT

OR

S

88

Sponsors & Exhibitors

SP

ON

SO

RS

& E

XH

IBIT

OR

S

89

SP

ON

SO

RS

& E

XH

IBIT

OR

S

90

Sponsors & Exhibitors

SP

ON

SO

RS

& E

XH

IBIT

OR

S

91

Sponsors & Exhibitors

92

Sponsors & Exhibitors